file_name,predicted_questionnaires,predicted_timepoints,Sponsor,TherapeuticArea,ground_truth_questionnaires,ground_truth_timepoints,Unnamed: 5,match_count,precision,recall,f1_score,matched_items,unmatched_predictions,unmatched_ground_truth
Protocol_06,"['Falls Efficacy Scale International (FES-I)', 'Geriatric Depression Scale (GDS)', 'Geriatric Anxiety Scale (GAS)', 'Apathy Evaluation Scale (AES)', 'Alternative Uses Task (AUT)', 'Quality of Life (QoL-AD) (QoL-AD)', 'Philadelphia Mindfulness Scale (PHLMS)']","['Assessment: Baseline 2  w/in 6 wks of intervention start', 'Assessment: Follow-up 1  0-7 days after intervention completion', 'Assessment: Baseline 2  w/in 6 wks of starting intervention', 'Assessment', 'Assessment: Baseline 2  w/in 6 wks of intervention start', 'Assessment: Follow-up 1  0-7 days after intervention completion', 'Assessment: Baseline 2  w/in 6 wks of starting intervention', 'Assessment', 'Assessment: Baseline 2  w/in 6 wks of intervention start', 'Assessment: Follow-up 1  0-7 days after intervention completion', 'Assessment: Baseline 2  w/in 6 wks of starting intervention', 'Assessment: Baseline 2  w/in 6 wks of intervention start', 'Assessment: Follow-up 1  0-7 days after intervention completion', 'Assessment: Baseline 2  w/in 6 wks of starting intervention', 'Assessment: Baseline 2  w/in 6 wks of intervention start', 'Assessment: Follow up 2  1-21 days after intervention completion', 'Assessment: Baseline 2  w/in 6 wks of starting intervention', 'Assessment: Follow-up 1  0-7 days after intervention completion', 'Assessment: Baseline 1  w/in 2 mos of phone screen and 14 weeks of intervention start', 'Assessment: Follow-up 1  0-7 days after intervention completion', 'Assessment: Baseline 1  w/in 2 mos of phone screen and 14 weeks of intervention start', 'Assessment: Follow up 2  1-21 days after intervention completion', 'Assessment: Baseline 1  w/in 2 mos of phone screen & 14 wks of intervention start']",National Center for Complementary and Integrative Health (NCCIH),Neurology,"[""Quality of Life in Alzheimer's Disease (QOL-AD)"", 'Short Form 36 (SF-36)', 'Zarit Caregiver Burden Scale (Zarit CBS)', 'Geriatric Anxiety Scale (GAS)', 'Geriatric Depression Scale (GDS)', 'Philadelphia Mindfulness Scale (PHLMS)', 'Falls Efficacy Scale International (FES-I)', 'Apathy Evaluation Scale (AES)', 'NEO Five Factor Inventory (NEO-FFI)']","['Assessment: Baseline 1 w/in 2 mos of phone screen and 14 weeks of intervention start', 'Assessment: Follow-up 1 0-7 days after intervention completion', 'Assessment: Baseline 2 w/in 6 wks of starting intervention', 'Assessment: Follow-up 1 0-7 days after intervention completion', 'Assessment: Baseline 2 w/in 6 wks of starting intervention', 'Assessment: Follow-up 1 0-7 days after intervention completion', 'Assessment: Baseline 2 w/in 6 wks of starting intervention', 'Assessment: Follow-up 1 0-7 days after intervention completion', 'Assessment: Baseline 2 w/in 6 wks of intervention start', 'Assessment: Baseline 2 w/in 6 wks of starting intervention', 'Assessment: Follow-up 1 0-7 days after intervention completion', 'Assessment: Baseline 2 w/in 6 wks of intervention start', 'Assessment: Baseline 1 w/in 2 mos of phone screen & 14 wks of intervention start', 'Assessment: Follow-up 2 1-21 days after intervention completion', 'Assessment: Baseline 1 w/in 2 mos of phone screen and 14 weeks of intervention start', 'Assessment: Baseline 2 w/in 6 wks of starting intervention', 'Assessment: Follow-up 1 0-7 days after intervention completion', 'Assessment: Baseline 2 w/in 6 wks of intervention start', 'Assessment: Baseline 2 w/in 6 wks of starting intervention', 'Assessment: Follow-up 1 0-7 days after intervention completion', 'Assessment: Baseline 2 w/in 6 wks of intervention start', 'Assessment: Baseline 2 w/in 6 wks of starting intervention']",,6.0,0.8571428571428571,0.6666666666666666,0.75,"['Geriatric Depression Scale (GDS) -> Geriatric Depression Scale (GDS) (1.00)', 'Falls Efficacy Scale International (FES-I) -> Falls Efficacy Scale International (FES-I) (1.00)', 'Geriatric Anxiety Scale (GAS) -> Geriatric Anxiety Scale (GAS) (1.00)', 'Apathy Evaluation Scale (AES) -> Apathy Evaluation Scale (AES) (1.00)', 'Philadelphia Mindfulness Scale (PHLMS) -> Philadelphia Mindfulness Scale (PHLMS) (1.00)', ""Quality of Life (QoL-AD) (QoL-AD) -> Quality of Life in Alzheimer's Disease (QOL-AD) (0.76)""]",['Alternative Uses Task (AUT)'],"['Short Form 36 (SF-36)', 'Zarit Caregiver Burden Scale (Zarit CBS)', 'NEO Five Factor Inventory (NEO-FFI)']"
Protocol_10,"['PRO Active Tool (PRO Tool)', ""St. George's Respiratory Questionnaire (SGRQ)"", ""King's Brief Illness Perception Questionnaire (K-BILD)"", 'UCSDSOBQ (University of California San Diego Shortness of Breath Questionnaire) (UCSDSOBQ)']","['Visit: 0   (Screening  )', 'Visit: 1', 'Visit: 2   (Treatment  ) (Interventional Period  )', 'Visit: 1', 'Visit: 2   (Treatment  ) (Interventional Period  )', 'Visit: 1', 'Visit: 2   (Treatment  ) (Interventional Period  )', 'Visit: 1', 'Visit: 2   (Treatment  ) (Interventional Period  )']",Boehringer Ingelheim,Pulmonology,"[""St. George's Respiratory Questionnaire (SGRQ)"", ""King's Brief Interstitial Lung Disease questionnaire (K-BILD)"", 'University of California, San Diego Shortness of Breath Questionnaire (UCSD-SOBQ)']","['Visit: 1', 'Visit: 2 (Treatment) (Interventional Period)', 'Visit: 5', 'Visit: 7 (EOT)', 'Visit: 1', 'Visit: 2 (Treatment) (Interventional Period)', 'Visit: 5', 'Visit: 7 (EOT)', 'Visit: 1', 'Visit: 2 (Treatment) (Interventional Period)', 'Visit: 5', 'Visit: 7 (EOT)']",,2.0,0.5,0.6666666666666666,0.5714285714285715,"[""St. George's Respiratory Questionnaire (SGRQ) -> St. George's Respiratory Questionnaire (SGRQ) (1.00)"", 'UCSDSOBQ (University of California San Diego Shortness of Breath Questionnaire) (UCSDSOBQ) -> University of California, San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) (0.94)']","['PRO Active Tool (PRO Tool)', ""King's Brief Illness Perception Questionnaire (K-BILD)""]","[""King's Brief Interstitial Lung Disease questionnaire (K-BILD)""]"
Protocol_47,"['Eczema-related Sleep numeric rating scale (Eczema-related Sleep NRS)', 'Worst Daily Pruritus numeric rating scale (Worst Daily Pruritus NRS)', 'Average Daily Pruritus numeric rating scale (Average Daily Pruritus NRS)', 'Patient Days of Topical Treatment Use (Patient Days of Topical Treatment Use)', 'Patient Global Impression of Bother (PGI-B)', 'Patient Global Impression of Severity (PGI-S)', 'Patient-Oriented Eczema Measure (POEM)', 'Dermatology Life Quality Index (DLQI)', 'EuroQoL 5-Dimension Health Questionnaire 5 Level (EQ-5D-5L)', 'Hospital Anxiety and Depression Scale (HADS)']","['Nominal  Week 16 visit  (if applicable)', 'Early termination  (if applicable)', 'Unscheduled visit (if  applicable)', 'Nominal  Week 16 visit  (if applicable)', 'Early termination  (if applicable)', 'Unscheduled visit (if  applicable)', 'Early termination  (if applicable)', 'Unscheduled visit (if  applicable)', 'Early termination  (if applicable)', 'Unscheduled visit (if  applicable)']",LEO Pharma A/S,Atopic dermatitis (AD),"['Eczema-related Sleep Numeric Rating Scale (Eczema-related Sleep NRS)', 'Worst Daily Pruritus Numeric Rating Scale (Worst Daily Pruritus NRS)', 'Average Daily Pruritus Numeric Rating Scale (Average Daily Pruritus NRS)', 'Patient Days of Topical Treatment Use', 'Patient Global Impression of Bother (PGI-B)', 'Patient Global Impression of Severity (PGI-S)', 'Patient Oriented Eczema Measure (POEM)', 'Dermatology Life Quality Index (DLQI)', 'EuroQoL 5-Dimension Health Questionnaire 5 Level (EQ-5D-5L)', 'Hospital Anxiety and Depression Scale (HADS)']",[],Some questionnaires match to any 'N/A' timeline point if the shortName is equal to 'N/A',10.0,1.0,1.0,1.0,"['Average Daily Pruritus numeric rating scale (Average Daily Pruritus NRS) -> Average Daily Pruritus Numeric Rating Scale (Average Daily Pruritus NRS) (1.00)', 'Dermatology Life Quality Index (DLQI) -> Dermatology Life Quality Index (DLQI) (1.00)', 'Eczema-related Sleep numeric rating scale (Eczema-related Sleep NRS) -> Eczema-related Sleep Numeric Rating Scale (Eczema-related Sleep NRS) (1.00)', 'Worst Daily Pruritus numeric rating scale (Worst Daily Pruritus NRS) -> Worst Daily Pruritus Numeric Rating Scale (Worst Daily Pruritus NRS) (1.00)', 'Patient Global Impression of Bother (PGI-B) -> Patient Global Impression of Bother (PGI-B) (1.00)', 'Patient Global Impression of Severity (PGI-S) -> Patient Global Impression of Severity (PGI-S) (1.00)', 'EuroQoL 5-Dimension Health Questionnaire 5 Level (EQ-5D-5L) -> EuroQoL 5-Dimension Health Questionnaire 5 Level (EQ-5D-5L) (1.00)', 'Hospital Anxiety and Depression Scale (HADS) -> Hospital Anxiety and Depression Scale (HADS) (1.00)', 'Patient-Oriented Eczema Measure (POEM) -> Patient Oriented Eczema Measure (POEM) (1.00)', 'Patient Days of Topical Treatment Use (Patient Days of Topical Treatment Use) -> Patient Days of Topical Treatment Use (0.94)']",[],[]
Protocol_30,"['Prostate Cancer Treatment Questionnaire (PCTQ)', 'Decisional Conflict Scale (DCS)', 'Expanded Prostate Cancer Index Composite Short Form (EPIC-26)', 'Decisional Regret Scale (DRS)']",['12 months after baseline**'],Alliance for Clinical Trials in Oncology,Oncology,"['Prostate Cancer Treatment Questionnaire (PCTQ)', 'Decisional Conflict Scale (DCS)', 'Expanded Prostate Cancer Index Composite Short Form (EPIC-26)', 'Decisional Regret Scale (DRS)']","['Baseline*', '12 months after baseline*', 'Baseline*', '12 months after baseline*']",Weird structure of Schedule of Events + Different names,4.0,1.0,1.0,1.0,"['Prostate Cancer Treatment Questionnaire (PCTQ) -> Prostate Cancer Treatment Questionnaire (PCTQ) (1.00)', 'Expanded Prostate Cancer Index Composite Short Form (EPIC-26) -> Expanded Prostate Cancer Index Composite Short Form (EPIC-26) (1.00)', 'Decisional Conflict Scale (DCS) -> Decisional Conflict Scale (DCS) (1.00)', 'Decisional Regret Scale (DRS) -> Decisional Regret Scale (DRS) (1.00)']",[],[]
Protocol_26,"['EORTC QLQ-BLM30 (QLQ-BLM30)', 'Quality of Life (QOL) forms (QOL)']","['Tests and procedures: Screening (<28 days prior to reg)', 'Tests and procedures: Screening (≤28 days prior to reg)']","Parminder Singh, MD",Oncology,"['European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)', 'European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Bladder Cancer Module (EORTC QLQ-BLM30)']","['Tests and procedures: Screening (<28 days prior to reg)', 'Tests and procedures: End of Treatment (30 days after last dose) (Monitoring)', 'Tests and procedures: EOS (12 Mo after registration) (Clinical Follow-up)', 'Tests and procedures: Screening (<28 days prior to reg)', 'Tests and procedures: End of Treatment (30 days after last dose) (Monitoring)', 'Tests and procedures: EOS (12 Mo after registration) (Clinical Follow-up)']",,0.0,0.0,0.0,0.0,[],"['EORTC QLQ-BLM30 (QLQ-BLM30)', 'Quality of Life (QOL) forms (QOL)']","['European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)', 'European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Bladder Cancer Module (EORTC QLQ-BLM30)']"
Protocol_27,"['Phonemic Fluency Test (Phonemic Fluency)', 'Letter-Number Sequencing Test (LNS)', 'Color Trails Test (CTT)', 'Montreal Cognitive Assessment (MoCA)', 'Progressive Supranuclear Palsy Quality of Life scale (PSP-QoL)']","['Procedure: Week0  (Day 1)', 'Procedure: Weeks 12,  24,36  (±3 days)', 'Procedure: 24 week intervals after Week 52d  (±7 days)', 'Procedure: Weeks 76, 100,  124,148,172,196  (±7 days)', 'Procedurea: Week 0  (Day 1)', 'Procedurea: (±3 days)  Weeks  12, 24, 36', 'Procedurea: Week 48  (±3 days)', 'Procedure: Screening Visit', 'Procedure: Week0  (Day 1)', 'Procedure: Weeks 12,  24,36  (±3 days)', 'Procedure: 24 week intervals after Week 52d  (±7 days)', 'Procedure: Weeks 76, 100,  124,148,172,196  (±7 days)', 'Procedurea: Week 0  (Day 1)', 'Procedurea: (±3 days)  Weeks  12, 24, 36', 'Procedurea: Week 48  (±3 days)', 'Procedure: Screening Visit', 'Procedure: Week0  (Day 1)', 'Procedure: Weeks 12,  24,36  (±3 days)', 'Procedure: Week48  (±3 days)', 'Procedure: Week 52  (±3 days)', 'Procedure: Early  Discontinuation,', 'Procedure: 24 week intervals after Week 52d  (±7 days)', 'Procedure: Weeks 76, 100,  124,148,172,196  (±7 days)', 'Procedurea: Week 0  (Day 1)', 'Procedurea: (±3 days)  Weeks  12, 24, 36', 'Procedurea: Week 48  (±3 days)', 'Procedure: Screening Visit', 'Procedure: Week0  (Day 1)', 'Procedure: Weeks 12,  24,36  (±3 days)', 'Procedure: 24 week intervals after Week 52d  (±7 days)', 'Procedurea: Week 0  (Day 1)', 'Procedurea: (±3 days)  Weeks  12, 24, 36', 'Procedurea: Week 48  (±3 days)', 'Procedure: Screening Visit', 'Procedure: Week0  (Day 1)', 'Procedure: Weeks 12,  24,36  (±3 days)', 'Procedure: Week48  (±3 days)', 'Procedure: Week 52  (±3 days)', 'Procedure: Early  Discontinuation,', 'Procedure: 12 week intervals after Week 52c  (±7 days)', 'Procedure: 24 week intervals after Week 52d  (±7 days)', 'Procedure: Weeks 64, 88,  112, 136, 160, 184  (±7 days)', 'Procedure: Weeks 76, 100,  124,148,172,196  (±7 days)']",Biogen MA Inc./Biogen Idec Research Limited/ Biogen Japan Ltd./Biogen Australia PTY Ltd.,Neurology,"['Progressive Supranuclear Palsy Quality of Life scale (PSP-QoL)', 'EuroQol (EQ-5D)']","['Procedure: Week 0 (Day 1)', 'Procedure: Weeks 12, 24, 36 (+3 days)', 'Procedure: Week 52 (+3 days)', 'Procedure: Early Discontinuation', 'Procedure: Weeks 76, 100, 124, 148, 172, 196 (+7 days)', 'Procedure: 24 week intervals after Week 52d (+7 days)']",,1.0,0.2,0.5,0.28571428571428575,['Progressive Supranuclear Palsy Quality of Life scale (PSP-QoL) -> Progressive Supranuclear Palsy Quality of Life scale (PSP-QoL) (1.00)'],"['Phonemic Fluency Test (Phonemic Fluency)', 'Letter-Number Sequencing Test (LNS)', 'Color Trails Test (CTT)', 'Montreal Cognitive Assessment (MoCA)']",['EuroQol (EQ-5D)']
Protocol_31,"['Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL)', 'Hemophilia Quality of Life Questionnaire for children and adolescents (Haemo-QOL)', 'Treatment Satisfaction Questionnaire for Medication (TSQM-9)', 'Hemophilia Activities List (HAL)', 'Pediatric Hemophilia Activities List (pedHAL)', 'EuroQol-5 Dimension (EQ-5D)']","['Study Day (±Visit Window)   (Study Visit (Month)  ): -60 to -1', 'Study Day (±Visit Window)   (Study Visit (Month)  ): Day 1  (Baseline ) (Onset Period  ) (Treatment Period  )', 'Study Day (±Visit Window)   (Study Visit (Month)  ): 15 ±3', 'Study Day (±Visit Window)   (Study Visit (Month)  ): 29 ±7   (Month 1 ) (Efficacy Period  )', 'Predose', 'Postdose 10 min (±5 min)d', 'Postdose 60 min (±5 min)d', 'Study Day (±Visit Window)   (Study Visit (Month)  ): Day 1  (Baseline ) (Onset Period  ) (Treatment Period  )', 'Study Day (±Visit Window)   (Study Visit (Month)  ): Day 1  (Baseline ) (Onset Period  ) (Treatment Period  )', 'Study Day (±Visit Window)   (Study Visit (Month)  ): Day 1  (Baseline ) (Onset Period  ) (Treatment Period  )', 'Study Day (±Visit Window)   (Study Visit (Month)  ): Day 1  (Baseline ) (Onset Period  ) (Treatment Period  )', 'Study Day (±Visit Window)   (Study Visit (Month)  ): Day 1  (Baseline ) (Onset Period  ) (Treatment Period  )']",Genzyme Corporation,Hematology,"['Hemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL)', 'Hemophilia Quality of Life Questionnaire for children and adolescents (Haemo-QOL)', 'Treatment Satisfaction Questionnaire for Medication (TSQM)', 'Hemophilia Activities List (HAL)', 'Pediatric Hemophilia Activities List (pedHAL)', 'EuroQol-5 dimension (EQ-5D)']","['Study Day (Â±Visit Window) (Study Visit (Month) ): Day 1 (Baseline ) (Onset Period ) (Treatment Period )', 'Study Day (+Visit Window) (Study Visit (Month)): Month 9 (EOS/ ET)', 'Study Day (Â±Visit Window) (Study Visit (Month) ): Day 1 (Baseline ) (Onset Period ) (Treatment Period )', 'Study Day (+Visit Window) (Study Visit (Month)): Month 9 (EOS/ ET)', 'Study Day (Â±Visit Window) (Study Visit (Month) ): Day 1 (Baseline ) (Onset Period ) (Treatment Period )', 'Study Day (+Visit Window) (Study Visit (Month)): Month 9 (EOS/ ET)', 'Study Day (Â±Visit Window) (Study Visit (Month) ): Day 1 (Baseline ) (Onset Period ) (Treatment Period )', 'Study Day (+Visit Window) (Study Visit (Month)): Month 9 (EOS/ ET)', 'Study Day (Â±Visit Window) (Study Visit (Month) ): Day 1 (Baseline ) (Onset Period ) (Treatment Period )', 'Study Day (+Visit Window) (Study Visit (Month)): Month 9 (EOS/ ET)', 'Study Day (Â±Visit Window) (Study Visit (Month) ): Day 1 (Baseline ) (Onset Period ) (Treatment Period )', 'Study Day (+Visit Window) (Study Visit (Month)): Month 9 (EOS/ ET)']",,6.0,1.0,1.0,1.0,"['Hemophilia Quality of Life Questionnaire for children and adolescents (Haemo-QOL) -> Hemophilia Quality of Life Questionnaire for children and adolescents (Haemo-QOL) (1.00)', 'Hemophilia Activities List (HAL) -> Hemophilia Activities List (HAL) (1.00)', 'Pediatric Hemophilia Activities List (pedHAL) -> Pediatric Hemophilia Activities List (pedHAL) (1.00)', 'EuroQol-5 Dimension (EQ-5D) -> EuroQol-5 dimension (EQ-5D) (1.00)', 'Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL) -> Hemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL) (0.96)', 'Treatment Satisfaction Questionnaire for Medication (TSQM-9) -> Treatment Satisfaction Questionnaire for Medication (TSQM) (0.96)']",[],[]
Protocol_46,"['Impact of Visual Impairment (IVI) (IVI)', 'EQ5D-5L (EQ5D-5L)', 'EQ5D-Y (EQ5D-Y)', 'Photoaversion Questionnaire (Baseline) (Photoaversion Baseline)', 'Photoaversion Device Questionnaire (After Surgery) (Photoaversion After Surgery)']",[],MeiraGTx UK II Ltd.,Gene Therapy for Achromatopsia (CNGA3),"['Impact of Visual Impairment questionnaire (IVI)', 'EQ5D-5L questionnaire (EQ5D-5L)', 'EQ5D-Y questionnaire (EQ5D-Y)']","['Baseline', 'W24', 'Baseline', 'W24', 'Baseline', 'W24']",Extracted tables data is missing.,1.0,0.2,0.3333333333333333,0.25,['Impact of Visual Impairment (IVI) (IVI) -> Impact of Visual Impairment questionnaire (IVI) (0.91)'],"['EQ5D-5L (EQ5D-5L)', 'EQ5D-Y (EQ5D-Y)', 'Photoaversion Questionnaire (Baseline) (Photoaversion Baseline)', 'Photoaversion Device Questionnaire (After Surgery) (Photoaversion After Surgery)']","['EQ5D-5L questionnaire (EQ5D-5L)', 'EQ5D-Y questionnaire (EQ5D-Y)']"
Protocol_11,"['Patient Reported Outcome Measurement Information System (PROMIS) – Pediatric Profile (PROMIS Pediatric)', 'Patient Reported Outcome Measurement Information System (PROMIS) – Adult Profile (PROMIS Adult)', 'EORTC QLQ-C30 (EORTC QLQ-C30)']","['Studies to be Obtained: Baseline', 'Studies to be Obtained: Prior to  Subsequent  Cycles', 'Studies to be Obtained: End of  Therapy', 'Studies to be Obtained: Baseline', 'Studies to be Obtained: Prior to  Subsequent  Cycles', 'Studies to be Obtained: End of  Therapy', 'Studies to be Obtained: Baseline', 'Studies to be Obtained: Prior to  Subsequent  Cycles', 'Studies to be Obtained: End of  Therapy']",St. Jude Children's Research Hospital,Oncology,"['PROMIS Pediatric Profile (PROMIS-37 Profile v.1.1)', 'PROMIS Adult Profile (PROMIS-43 Profile v.2.0)']","['Studies to be Obtained: Prior to Subsequent Cycles', 'Studies to be Obtained: End of Therapy', 'Studies to be Obtained: Baseline', 'Studies to be Obtained: Prior to Subsequent Cycles', 'Studies to be Obtained: End of Therapy', 'Studies to be Obtained: Baseline']",,1.0,0.3333333333333333,0.5,0.4,['Patient Reported Outcome Measurement Information System (PROMIS) – Pediatric Profile (PROMIS Pediatric) -> PROMIS Pediatric Profile (PROMIS-37 Profile v.1.1) (0.84)'],"['Patient Reported Outcome Measurement Information System (PROMIS) – Adult Profile (PROMIS Adult)', 'EORTC QLQ-C30 (EORTC QLQ-C30)']",['PROMIS Adult Profile (PROMIS-43 Profile v.2.0)']
Protocol_07,['University of Washington Quality of Life Questionnaire Version 4 (UW-QoLQ v4)'],"['Baseline1', '~12-16 Weeks Post Treatment', 'Follow-Up2', 'About 12-16 W Post Surgery']",Roswell Park Cancer Institute,Oncology,['University of Washington Quality of Life Questionnaire Version 4 (UW-QoLQ v4)'],"['Baseline1, ~12-16 Weeks Post Treatment', 'Follow-Up2', 'About 12-16 W Post Surgery']",,1.0,1.0,1.0,1.0,['University of Washington Quality of Life Questionnaire Version 4 (UW-QoLQ v4) -> University of Washington Quality of Life Questionnaire Version 4 (UW-QoLQ v4) (1.00)'],[],[]
Protocol_50,['Venous Insufficiency Epidemiological and Economic Study - Quality of Life Questionnaire (VEINES-QOL/Sym)'],"['Visit: Visit 2', 'Visit: Visit 3', 'Visit: Visit 4', 'Visit: Visit 5', 'Visit: Visit 6']","Vascular Insights, LLC",Vascular Surgery,"['VEINES-QOL/Sym Questionnaire (VEINES-QOL/Sym)', 'European Quality of Life Scale (EQ-5D-5L)', 'Wong Baker Visual Analog Pain Scale (VAS)']","['Visit: Visit 2', 'Visit: Visit 3', 'Visit: Visit 4', 'Visit: Visit 5', 'Visit: Visit 6', 'Visit: Visit 2', 'Visit: Visit 3', 'Visit: Visit 4', 'Visit: Visit 5', 'Visit: Visit 6', 'Visit: Visit 2', 'Visit: Visit 3', 'Visit: Visit 4', 'Visit: Visit 5', 'Visit: Visit 6']",,0.0,0.0,0.0,0.0,[],['Venous Insufficiency Epidemiological and Economic Study - Quality of Life Questionnaire (VEINES-QOL/Sym)'],"['VEINES-QOL/Sym Questionnaire (VEINES-QOL/Sym)', 'European Quality of Life Scale (EQ-5D-5L)', 'Wong Baker Visual Analog Pain Scale (VAS)']"
Protocol_36,"['Epistaxis Severity Score (ESS)', 'SF-36 Quality of Life Questionnaire (SF-36)']","['', 'Inclusion  V1 J0', 'V2  D43 (to 50)', 'V3  D85 (to 100)', 'Inclusion  V1 J0', 'V2  D43 (to 50)', 'V3  D85 (to 100)']",Hospices Civils de Lyon,Hemorrhagic Hereditary Telangiectasia (HHT),"['SF36 Quality of Life Questionnaire (SF36)', 'Epistaxis Severity Score (ESS)']","['Inclusion V1 JO', 'V2 D43 (to 50)', 'V3 D85 (to 100)', 'Inclusion V1 JO', 'V2 D43 (to 50)', 'V3 D85 (to 100)']",,2.0,1.0,1.0,1.0,"['Epistaxis Severity Score (ESS) -> Epistaxis Severity Score (ESS) (1.00)', 'SF-36 Quality of Life Questionnaire (SF-36) -> SF36 Quality of Life Questionnaire (SF36) (0.92)']",[],[]
Protocol_20,['Quality of Life Assessment (FKSI-19)'],"['Day:   (Treatment Cycle/Title:  ) (Trial Phase:  ): -3 to 1   (Baseline (Visit 2)a,b  )', 'Day:   (Treatment Cycle/Title:  ) (Trial Phase:  ): 43   (3  )', 'Day:   (Treatment Cycle/Title:  ) (Trial Phase:  ): Within 14 days of last dose of lenvatinib   (Post-Treatment Phase  )']","Mehmet Asim Bilen, MD",Oncology(Renal Cell Carcinoma (RCC)),['Functional Assessment of Cancer Therapy-Kidney Specific Index-19 (FKSI-19)'],"['Day: (Treatment Cycle/Title:) (Trial Phase: ): -3 to 1 (Baseline (Visit 2)a,b)', 'Day: (Treatment Cycle/Title:) (Trial Phase: ): 43 (3)', 'Day: (Treatment Cycle/Title:) (Trial Phase: ): Within 14 days of last dose of lenvatinib (Post-Treatment Phase )']",,0.0,0.0,0.0,0.0,[],['Quality of Life Assessment (FKSI-19)'],['Functional Assessment of Cancer Therapy-Kidney Specific Index-19 (FKSI-19)']
Protocol_16,"['Symptom diary (Symptom diary for reactogenicity events)', 'Health-Related Quality of Life (HRQOL) (HRQOL Assessment)', 'EuroQOL 5 Dimensions - 5 Level (EQ-5D-5L) (EQ-5D-5L)', 'EuroQOL Visual Analogue Scale (EQ VAS) (EQ VAS)', 'REDCap electronic diaries (REDCap Diary)']",[],Centers for Disease Control & Prevention (CDC),Infectious Diseases,"['EuroQOL 5 dimensions-5 level (EQ-5D-5L)', 'EuroQOL Visual Analogue Scale (EQ VAS)']","['Procedure (Table 7: Third Dose Schedule): Visit 1 (of Events)', 'Procedure (Table 7: Third Dose Schedule): Visit 1a', 'Procedure (Table 7: Third Dose Schedule): Visit 1 (of Events)', 'Procedure (Table 7: Third Dose Schedule): Visit 1a']",,2.0,0.4,1.0,0.5714285714285715,"['EuroQOL Visual Analogue Scale (EQ VAS) (EQ VAS) -> EuroQOL Visual Analogue Scale (EQ VAS) (0.99)', 'EuroQOL 5 Dimensions - 5 Level (EQ-5D-5L) (EQ-5D-5L) -> EuroQOL 5 dimensions-5 level (EQ-5D-5L) (0.98)']","['Symptom diary (Symptom diary for reactogenicity events)', 'Health-Related Quality of Life (HRQOL) (HRQOL Assessment)', 'REDCap electronic diaries (REDCap Diary)']",[]
Protocol_41,"['Abbreviated Profile of Hearing Aid Benefit (APHAB)', 'Speech, Spatial and Qualities of Hearing Scale (SSQ-12)', 'Health Utilities Index (HUI3)']","['-: Screening  And  Baseline', '-: Follow up  3M', '-: - Follow up  6M', '-: Screening  And  Baseline', '-: Follow up  3M', '-: - Follow up  6M', '-: Screening  And  Baseline', '-: Follow up  3M', '-: - Follow up  6M']",Cochlear Bone Anchored Solutions AB,Otolaryngology,"['Abbreviated Profile of Hearing Aid Benefit (APHAB)', 'Speech, Spatial and Qualities of Hearing Scale (SSQ)', 'Health Utilities Index (HUI)']","['Screening And Baseline', 'Follow up 3M', 'Follow up 6M', 'Screening And Baseline', 'Follow up 3M', 'Follow up 6M', 'Screening And Baseline', 'Follow up 3M', 'Follow up 6M']",,3.0,1.0,1.0,1.0,"['Abbreviated Profile of Hearing Aid Benefit (APHAB) -> Abbreviated Profile of Hearing Aid Benefit (APHAB) (1.00)', 'Health Utilities Index (HUI3) -> Health Utilities Index (HUI) (0.98)', 'Speech, Spatial and Qualities of Hearing Scale (SSQ-12) -> Speech, Spatial and Qualities of Hearing Scale (SSQ) (0.96)']",[],[]
Protocol_40,"['Hemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL)', 'Hemophilia Quality of Life Questionnaire for Children and Adolescents (Haemo-QOL)', 'Treatment Satisfaction Questionnaire for Medication (TSQM-9)', 'Hemophilia Activities List (HAL)', 'Pediatric Hemophilia Activities List (pedHAL)', 'EuroQol 5-Dimension 5-Level (EQ-5D-5L)']","['Study Visit (Month)  Study Day (±Visit Window): -60 to -1   (Screening  )', 'Study Visit (Month)  Study Day (±Visit Window): Day 1  (Baseline ) (Onset Period  ) (Treatment Period  )', 'Study Visit (Month)  Study Day (±Visit Window): 15 ±3', 'Study Visit (Month)  Study Day (±Visit Window): 29 ±7   (Month 1 ) (Efficacy Period  )', 'Predose', 'Postdose 10 min (±5 min)d', 'Postdose 60 min (±5 min)d', 'Study Visit (Month)  Study Day (±Visit Window): Day 1  (Baseline ) (Onset Period  ) (Treatment Period  )', 'Study Visit (Month)  Study Day (±Visit Window): Day 1  (Baseline ) (Onset Period  ) (Treatment Period  )', 'Study Visit (Month)  Study Day (±Visit Window): Day 1  (Baseline ) (Onset Period  ) (Treatment Period  )', 'Study Visit (Month)  Study Day (±Visit Window): Day 1  (Baseline ) (Onset Period  ) (Treatment Period  )', 'Study Visit (Month)  Study Day (±Visit Window): Day 1  (Baseline ) (Onset Period  ) (Treatment Period  )']",Sanofi Genzyme Corporation,Hematology,"['Hemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL)', 'Treatment Satisfaction Questionnaire for Medication (TSQM)', 'Hemophilia Activities List (HAL)', 'Pediatric Hemophilia Activities List (pedHAL)', 'EuroQol-5 Dimension (EQ-5D)', 'Hemophilia Quality of Life Questionnaire for Children and Adolescents (Haemo-QOL)']","['Study Visit (Month) Study Day (Â±Visit Window): Day 1 (Baseline ) (Onset Period ) (Treatment Period )', 'Study Visit (Month): EOS/ ET', 'Study Visit (Month) Study Day (Â±Visit Window): Day 1 (Baseline ) (Onset Period ) (Treatment Period )', 'Study Visit (Month): EOS/ ET', 'Study Visit (Month) Study Day (Â±Visit Window): Day 1 (Baseline ) (Onset Period ) (Treatment Period )', 'Study Visit (Month): EOS/ ET', 'Study Visit (Month) Study Day (Â±Visit Window): Day 1 (Baseline ) (Onset Period ) (Treatment Period )', 'Study Visit (Month): EOS/ ET', 'Study Visit (Month) Study Day (Â±Visit Window): Day 1 (Baseline ) (Onset Period ) (Treatment Period )', 'Study Visit (Month): EOS/ ET', 'Study Visit (Month) Study Day (Â±Visit Window): Day 1 (Baseline ) (Onset Period ) (Treatment Period )', 'Study Visit (Month): EOS/ ET']",Schedule of Events Timepoints written vertically,6.0,1.0,1.0,1.0,"['Hemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL) -> Hemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL) (1.00)', 'Hemophilia Quality of Life Questionnaire for Children and Adolescents (Haemo-QOL) -> Hemophilia Quality of Life Questionnaire for Children and Adolescents (Haemo-QOL) (1.00)', 'Hemophilia Activities List (HAL) -> Hemophilia Activities List (HAL) (1.00)', 'Pediatric Hemophilia Activities List (pedHAL) -> Pediatric Hemophilia Activities List (pedHAL) (1.00)', 'Treatment Satisfaction Questionnaire for Medication (TSQM-9) -> Treatment Satisfaction Questionnaire for Medication (TSQM) (0.96)', 'EuroQol 5-Dimension 5-Level (EQ-5D-5L) -> EuroQol-5 Dimension (EQ-5D) (0.89)']",[],[]
Protocol_17,['Skindex-16 Questionnaire (Skindex-16)'],"['2   (Phase of the study  )', '2   (Phase of the study  ): 3   (Screening  )', '2   (Phase of the study  ): 4   (RT &  treatment start  )', '2   (Phase of the study  ): 5   (RT (expected 33-35 sessions)  )', '2   (Phase of the study  ): 6', '2   (Phase of the study  ): 7', '2   (Phase of the study  ): 8', '2   (Phase of the study  ): 9', '2   (Phase of the study  ): 10', 'Visit number   (Phase of the study  )', 'Visit number   (Phase of the study  ): 1   (Screening  )', 'Visit number   (Phase of the study  ): 2   (RT &  treatment start  )', 'Visit number   (Phase of the study  ): 3   (RT (expected 30 sessions)  )', 'Visit number   (Phase of the study  ): 4', 'Visit number   (Phase of the study  ): 5', 'Visit number   (Phase of the study  ): 6', 'Visit number   (Phase of the study  ): 7', 'Visit number   (Phase of the study  ): 8   (RT  end  )', 'Visit number   (Phase of the study  ): 9   (2 weeks treatment without RT  )', 'Visit number   (Phase of the study  ): 3   (RT (expected 33-35 sessions)  )', 'Visit number   (Phase of the study  ): 8', 'Visit number   (Phase of the study  ): 9   (RT  end  )', 'Visit number   (Phase of the study  ): 10   (2 weeks treatment without RT  )', '2   (Phase of the study  ): 5   (RT (expected 30 sessions)  )']",Helsinn Healthcare SA,Oncology & Dermatology,"['Skindex-16 Questionnaire (Skindex-16)', 'Patient Global Satisfaction Score (Likert Scale)']","['Week (Visit number) (Phase of the study): 7 (9) (RT end)', 'Week (Visit number) (Phase of the study): 9 (10) (2 weeks treatment without RT)', 'Visit number (Phase of the study): 8 (RT end)', 'Visit number (Phase of the study): 9 (2 weeks treatment without RT)']","Weird table, different visit numbers between tables",1.0,1.0,0.5,0.6666666666666666,['Skindex-16 Questionnaire (Skindex-16) -> Skindex-16 Questionnaire (Skindex-16) (1.00)'],[],['Patient Global Satisfaction Score (Likert Scale)']
Protocol_01,"['Dermatology Life Quality Index (DLQI)', 'PSO-TARGET QoL Component grid (PSO-TARGET grid)']","['Reporter: Base-line Visit (Day 0)', 'Reporter: 3 months Visit (week 12-16)', 'Reporter: 12 months visit (week 48-56)', 'Reporter: Base-line Visit (Day 0)', 'Reporter: 3 months Visit (week 12-16)', 'Reporter: 12 months visit (week 48-56)']",LEO Pharma France,Dermatogoly,"['Dermatology Life Quality Index (DLQI)', 'PSO-TARGET Quality of Life Component Grid (PSO-TARGET QoL Component Grid)']","['Reporter: Base-line Visit (Day 0)', 'Reporter: 3 months Visit (week 12-16)', 'Reporter: 12 months visit (week 48-56)', 'Reporter: Base-line Visit (Day 0)', 'Reporter: 3 months Visit (week 12-16)', 'Reporter: 12 months visit (week 48-56)']",,2.0,1.0,1.0,1.0,"['Dermatology Life Quality Index (DLQI) -> Dermatology Life Quality Index (DLQI) (1.00)', 'PSO-TARGET QoL Component grid (PSO-TARGET grid) -> PSO-TARGET Quality of Life Component Grid (PSO-TARGET QoL Component Grid) (0.80)']",[],[]
Protocol_21,"['Multi-Ligament Quality of Life (MLQoL) Questionnaire (MLQoL)', 'International Knee Documentation Committee Subjective Knee Form (IKDC-SKF)', 'Patient Reported Outcome Measurement Information System (PROMIS) Physical Function Scale (PROMIS PF)', 'PROMIS Global 10 (PROMIS Global 10)', 'Patient Acceptable Symptom State/Global Rating of Change (PASS/Global Rating of Change)', 'Tampa Scale for Kinesiophobia (TSK)', 'Brief Resilience Scale (Brief Resilience Scale)', 'Patient Reported Rehabilitation (Patient Reported Rehabilitation)']",[],Department of Defense (DoD),Orthopedic Surgery,"['Multiple Ligament Quality of Life Questionnaire (MLQoL)', 'Patient Reported Outcome Measurement Information System Physical Function Scale (PROMIS PF)', 'PROMIS Global 10 (PROMIS Global 10)', 'International Knee Documentation Committee Subjective Knee Form (IKDC-SKF)', 'Patient Acceptable Symptom State (PASS)', 'Global Rating of Change (GRC)', 'Tampa Scale for Kinesiophobia (TSK)', 'Brief Resilience Scale (BRS)', 'Functional Comorbidity Index (FCI)']","['Forms: Baseline (Screening/)', 'Forms: Surgery (Pre-Op/)', 'Forms: 6 m', 'Forms: 12 m', 'Forms: 24 m', 'Forms: Baseline (Screening/)', 'Forms: Surgery (Pre-Op/)', 'Forms: 6 m', 'Forms: 12 m', 'Forms: 24 m', 'Forms: Baseline (Screening/)', 'Forms: 6 m', 'Forms: 12 m', 'Forms: 24 m', 'Forms: Baseline (Screening/)', 'Forms: Surgery (Pre-Op/)', 'Forms: 6 m', 'Forms: 12 m', 'Forms: 24 m', 'Forms: Baseline (Screening/)', 'Forms: Surgery (Pre-Op/)', 'Forms: 6 m', 'Forms: 12 m', 'Forms: 24 m', 'Forms: Baseline (Screening/)', 'Forms: Surgery (Pre-Op/)', 'Forms: 6 m', 'Forms: 12 m', 'Forms: 24 m', 'Forms: Baseline (Screening/)', 'Forms: 6 m', 'Forms: 12 m', 'Forms: 24 m', 'Forms: Baseline (Screening/)', 'Forms: 6 m', 'Forms: 12 m', 'Forms: 24 m', 'Forms: Baseline (Screening/)']",,6.0,0.75,0.6666666666666666,0.7058823529411765,"['PROMIS Global 10 (PROMIS Global 10) -> PROMIS Global 10 (PROMIS Global 10) (1.00)', 'Tampa Scale for Kinesiophobia (TSK) -> Tampa Scale for Kinesiophobia (TSK) (1.00)', 'International Knee Documentation Committee Subjective Knee Form (IKDC-SKF) -> International Knee Documentation Committee Subjective Knee Form (IKDC-SKF) (1.00)', 'Multi-Ligament Quality of Life (MLQoL) Questionnaire (MLQoL) -> Multiple Ligament Quality of Life Questionnaire (MLQoL) (0.98)', 'Patient Reported Outcome Measurement Information System (PROMIS) Physical Function Scale (PROMIS PF) -> Patient Reported Outcome Measurement Information System Physical Function Scale (PROMIS PF) (0.98)', 'Brief Resilience Scale (Brief Resilience Scale) -> Brief Resilience Scale (BRS) (0.89)']","['Patient Acceptable Symptom State/Global Rating of Change (PASS/Global Rating of Change)', 'Patient Reported Rehabilitation (Patient Reported Rehabilitation)']","['Patient Acceptable Symptom State (PASS)', 'Global Rating of Change (GRC)', 'Functional Comorbidity Index (FCI)']"
Protocol_37,"['Angioedema Quality of Life Questionnaire (AE-QoL)', 'EuroQoL 5-dimensional, 5-level questionnaire (EQ-5D-5L)', 'Treatment Satisfaction Questionnaire for Medication (TSQM)', 'Work Productivity and Activity Impairment Questionnaire (WPAI)']","['Assessment: Week 60 Day 421 ± 6 days', 'Assessment: Week 72 Day 505 ± 6 days', 'Assessment: Week 84 Day 589 ± 6 days', 'Assessment: Week 96 Day 673 ± 6 days', 'Assessment: Week 104 (Day 729 ± 7 days)', 'Assessment: Part 1 Double-Blind, Placebo-Controlled Study Drug Administration', 'Assessment: Week 60 Day 421 ± 6 days', 'Assessment: Week 72 Day 505 ± 6 days', 'Assessment: Week 84 Day 589 ± 6 days', 'Assessment: Week 96 Day 673 ± 6 days', 'Assessment: Week 104 (Day 729 ± 7 days)', 'Assessment: Part 1 Double-Blind, Placebo-Controlled Study Drug Administration', 'Assessment: Week 60 Day 421 ± 6 days', 'Assessment: Week 72 Day 505 ± 6 days', 'Assessment: Week 84 Day 589 ± 6 days', 'Assessment: Week 96 Day 673 ± 6 days', 'Assessment: Week 104 (Day 729 ± 7 days)', 'Assessment: Part 1 Double-Blind, Placebo-Controlled Study Drug Administration', 'Assessment: Week 60 Day 421 ± 6 days', 'Assessment: Week 72 Day 505 ± 6 days', 'Assessment: Week 84 Day 589 ± 6 days', 'Assessment: Week 96 Day 673 ± 6 days', 'Assessment: Week 104 (Day 729 ± 7 days)', 'Assessment: Part 1 Double-Blind, Placebo-Controlled Study Drug Administration']","BioCryst Pharmaceuticals, Inc. (BioCryst)",Hereditary Angioedema (HAE),"['Angioedema Quality of Life Questionnaire (AE-QoL)', 'EuroQol 5-Dimension 5-Level (EQ-5D-5L)', 'Treatment Satisfaction Questionnaire for Medication (TSQM)', 'Work Productivity and Activity Impairment Questionnaire (WPAI)']","['Assessment: Day 1 (Baseline)', 'Assessment: Week 4 Day 29 + 2 days', 'Assessment: Week 8 Day 57 + 2 days', 'Assessment: Week 12 Day 85 + 2 days', 'Assessment: Week 18 Day 127 + 2 days', 'Assessment: Week 24 Day 169d', 'Assessment: Week 28 Day 197 + 2 days', 'Assessment: Week 32 Day 225 + 2 days', 'Assessment: Week 36 Day 253 + 2 days', 'Assessment: Week 48 Day 337 + 7 days', 'Assessment: Week 52 (Day 365) + 2 days', 'Assessment: Week 60 Day 421 + 6 days', 'Assessment: Week 72 Day 505 + 6 days', 'Assessment: Week 84 Day 589 + 6 days', 'Assessment: Week 96 Day 673 + 6 days', 'Assessment: Week 104 (Day 729 7 days)', 'Assessment: Day 1 (Baseline)', 'Assessment: Week 4 Day 29 + 2 days', 'Assessment: Week 8 Day 57 + 2 days', 'Assessment: Week 12 Day 85 + 2 days', 'Assessment: Week 18 Day 127 + 2 days', 'Assessment: Week 24 Day 169d', 'Assessment: Week 28 Day 197 + 2 days', 'Assessment: Week 32 Day 225 + 2 days', 'Assessment: Week 36 Day 253 + 2 days', 'Assessment: Week 48 Day 337 + 7 days', 'Assessment: Week 52 (Day 365) + 2 days', 'Assessment: Week 60 Day 421 + 6 days', 'Assessment: Week 72 Day 505 + 6 days', 'Assessment: Week 84 Day 589 + 6 days', 'Assessment: Week 96 Day 673 + 6 days', 'Assessment: Week 104 (Day 729 7 days)', 'Assessment: Day 1 (Baseline)', 'Assessment: Week 4 Day 29 + 2 days', 'Assessment: Week 8 Day 57 + 2 days', 'Assessment: Week 12 Day 85 + 2 days', 'Assessment: Week 18 Day 127 + 2 days', 'Assessment: Week 24 Day 169d', 'Assessment: Week 28 Day 197 + 2 days', 'Assessment: Week 32 Day 225 + 2 days', 'Assessment: Week 36 Day 253 + 2 days', 'Assessment: Week 48 Day 337 + 7 days', 'Assessment: Week 52 (Day 365) + 2 days', 'Assessment: Week 60 Day 421 + 6 days', 'Assessment: Week 72 Day 505 + 6 days', 'Assessment: Week 84 Day 589 + 6 days', 'Assessment: Week 96 Day 673 + 6 days', 'Assessment: Week 104 (Day 729 7 days)', 'Assessment: Day 1 (Baseline)', 'Assessment: Week 4 Day 29 + 2 days', 'Assessment: Week 8 Day 57 + 2 days', 'Assessment: Week 12 Day 85 + 2 days', 'Assessment: Week 18 Day 127 + 2 days', 'Assessment: Week 24 Day 169d', 'Assessment: Week 28 Day 197 + 2 days', 'Assessment: Week 32 Day 225 + 2 days', 'Assessment: Week 36 Day 253 + 2 days', 'Assessment: Week 48 Day 337 + 7 days', 'Assessment: Week 52 (Day 365) + 2 days', 'Assessment: Week 60 Day 421 + 6 days', 'Assessment: Week 72 Day 505 + 6 days', 'Assessment: Week 84 Day 589 + 6 days', 'Assessment: Week 96 Day 673 + 6 days', 'Assessment: Week 104 (Day 729 7 days)']",,3.0,0.75,0.75,0.75,"['Treatment Satisfaction Questionnaire for Medication (TSQM) -> Treatment Satisfaction Questionnaire for Medication (TSQM) (1.00)', 'Work Productivity and Activity Impairment Questionnaire (WPAI) -> Work Productivity and Activity Impairment Questionnaire (WPAI) (1.00)', 'Angioedema Quality of Life Questionnaire (AE-QoL) -> Angioedema Quality of Life Questionnaire (AE-QoL) (1.00)']","['EuroQoL 5-dimensional, 5-level questionnaire (EQ-5D-5L)']",['EuroQol 5-Dimension 5-Level (EQ-5D-5L)']
Protocol_22,"['International Consultation on Incontinence Modular Questionnaire - Overactive Bladder Symptoms Quality of Life Questionnaire (ICIQ-OABqol) (ICIQ-OABqol)', '3-Day Voiding Diary (Voiding Diary)']","['Enrollment /  Baseline', '12-Week Follow-Up Visit (+/- 7 days)', 'Enrollment /  Baseline', 'Therapy Evaluation', '6-Week Follow-Up Visit (+/- 7 days)', '12-Week Follow-Up Visit (+/- 7 days)', 'Unscheduled Visit']","Medtronic, Inc. / Medtronic International Trading SÃ rl / Medtronic of Canada",Overactive Bladder (OAB),['International Consultation on Incontinence Questionnaire - Overactive Bladder Quality of Life (ICIQ-OABqol)'],"['Enrollment / Baseline', '12-Week Follow-Up Visit (+/- 7 days)']",,1.0,0.5,1.0,0.6666666666666666,['International Consultation on Incontinence Modular Questionnaire - Overactive Bladder Symptoms Quality of Life Questionnaire (ICIQ-OABqol) (ICIQ-OABqol) -> International Consultation on Incontinence Questionnaire - Overactive Bladder Quality of Life (ICIQ-OABqol) (0.98)'],['3-Day Voiding Diary (Voiding Diary)'],[]
Protocol_34,"['Functional Assessment of Cancer Therapy – Bone Marrow Transplant (FACT-BMT)', 'Patient Reported Outcomes Measurement Information System – Depression (PROMIS-D)', 'Post-Traumatic Stress Syndrome Scale 14 (PTSS-14)']",[],Lineberger Comprehensive Cancer Center,Supportive care in oncology,"['Functional Assessment of Cancer Therapy – Bone Marrow Transplant (FACT-BMT)', 'Patient Reported Outcomes Measurement Information System Depression (PROMIS-D)', 'Post Traumatic Stress Syndrome Scale 14 (PTSS-14)']","['Baseline (Pre- Transplant)', 'F1', 'F2', 'F3', 'Baseline (Pre- Transplant)', 'F1', 'F2', 'F3', 'Baseline (Pre- Transplant)', 'F1', 'F2', 'F3']","Instead of an X,  the mark is a point which might be confusing for textract",3.0,1.0,1.0,1.0,"['Functional Assessment of Cancer Therapy – Bone Marrow Transplant (FACT-BMT) -> Functional Assessment of Cancer Therapy – Bone Marrow Transplant (FACT-BMT) (1.00)', 'Post-Traumatic Stress Syndrome Scale 14 (PTSS-14) -> Post Traumatic Stress Syndrome Scale 14 (PTSS-14) (1.00)', 'Patient Reported Outcomes Measurement Information System – Depression (PROMIS-D) -> Patient Reported Outcomes Measurement Information System Depression (PROMIS-D) (0.99)']",[],[]
Protocol_18,"['Asthma Control Questionnaire (ACQ-7) (ACQ-7)', 'Asthma Quality of Life Questionnaire (AQLQ) (AQLQ)']","['Visit number   (Period  ): 101   (Run-in  )', 'Visit number   (Period  ): 201   (Treatment  )', 'Visit number   (Period  ): 203', 'Visit number   (Period  ): 204', 'Visit number   (Period  ): TD', 'Visit number   (Period  ): 201   (Treatment  )', 'Visit number   (Period  ): 203', 'Visit number   (Period  ): 204', 'Visit number   (Period  ): TD']",Novartis,Asthma,"['Asthma Quality of Life Questionnaire (AQLQ)', 'Asthma Control Questionnaire  (ACQ-7)']","['Visit number (Period): 201 (Treatment)', 'Visit number (Period): 203', 'Visit number (Period): 204', 'Visit number (Period): TD', 'Visit number (Period): 101 (Run-in)', 'Visit number (Period): 201 (Treatment)', 'Visit number (Period): 203', 'Visit number (Period): 204', 'Visit number (Period): TD']",,2.0,1.0,1.0,1.0,"['Asthma Quality of Life Questionnaire (AQLQ) (AQLQ) -> Asthma Quality of Life Questionnaire (AQLQ) (0.99)', 'Asthma Control Questionnaire (ACQ-7) (ACQ-7) -> Asthma Control Questionnaire  (ACQ-7) (0.99)']",[],[]
Protocol_38,"['EORTC QLQ-CIPN20 (QLQ-CIPN20)', 'Quality of Life Assessment (QoL)']",[],Karyopharm Therapeutics Inc.,Multiple myeloma (Oncology),['European Organization for Research and Treatment of Cancer Chemotherapy-induced Peripheral Neuropathy (QLQ-CIPN20) (EORTC QLQ-CIPN20)'],[],Extracted tables data is missing.,0.0,0.0,0.0,0.0,[],"['EORTC QLQ-CIPN20 (QLQ-CIPN20)', 'Quality of Life Assessment (QoL)']",['European Organization for Research and Treatment of Cancer Chemotherapy-induced Peripheral Neuropathy (QLQ-CIPN20) (EORTC QLQ-CIPN20)']
Protocol_43,"['EORTC Quality of Life Questionnaire (QLQ-C30)', 'EuroQOL 5-dimensions (EQ-5D-5L)', 'Healthcare Resource Utilization Questionnaire (HRU)']","['Base Date   (Visit  ): Day 1   (Every Cycle  )', 'Base Date   (Visit  ): Date of Last Dose   (End of Treatment1  )', 'Base Date   (Visit  ): Date of last Dose + 30 days   (Follow-up2  )', 'Base Date   (Visit  ): Day 1   (Every Cycle  )', 'Base Date   (Visit  ): Date of Last Dose   (End of Treatment1  )', 'Base Date   (Visit  ): Date of last Dose + 30 days   (Follow-up2  )', 'Base Date   (Visit  ): Day 1   (Every Cycle  )', 'Base Date   (Visit  ): Date of Last Dose   (End of Treatment1  )', 'Base Date   (Visit  ): Date of last Dose + 30 days   (Follow-up2  )', 'Base Date   (Visit  ): Date of Last Dose   (End of Treatment21  )', 'Base Date   (Visit  ): Date of last Dose +30 days   (Follow-up18  )']","Astellas Pharma Global Development, Inc. (APGD)",Oncology (Urothelial cancer),"['European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)', 'EuroQOL 5-dimensions 5-Level Questionnaire (EQ-5D-5L)']","['Base Date (Visit): Day -7 to -1 (Screening/Baseline 1)', 'Base Date (Visit): Day 1 (Every Cycle )', 'Base Date (Visit): Date of Last Dose (End of Treatment1)', 'Base Date (Visit): Date of last Dose + 30 days (Follow-up2)', 'Base Date (Visit): Day -7 to -1 (Screening/Baseline 1)', 'Base Date (Visit): Day 1 (Every Cycle )', 'Base Date (Visit): Date of Last Dose (End of Treatment1)', 'Base Date (Visit): Date of last Dose + 30 days (Follow-up2)']",2 different Shcedule of Events,1.0,0.3333333333333333,0.5,0.4,['EORTC Quality of Life Questionnaire (QLQ-C30) -> European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (0.81)'],"['EuroQOL 5-dimensions (EQ-5D-5L)', 'Healthcare Resource Utilization Questionnaire (HRU)']",['EuroQOL 5-dimensions 5-Level Questionnaire (EQ-5D-5L)']
Protocol_14,"['Chronic Respiratory Questionnaire (CRQ)', 'Linear Analog Self-Assessment (LASA)']","['Baseline', 'At 3 and 6 months after surgery*', 'Baseline', 'At 3 and 6 months after surgery*']",Alliance for Clinical Trials in Oncology,Oncology,"['Chronic Respiratory Questionnaire (CRQ)', 'Medical Research Council Dyspnea Score (MRC)', 'Linear Analog Self-Assessment (LASA)']","['Baseline', 'At 3 and 6 months after surgery*', 'Baseline', 'At 3 and 6 months after surgery*', 'Baseline', 'At 3 and 6 months after surgery*']",,2.0,1.0,0.6666666666666666,0.8,"['Chronic Respiratory Questionnaire (CRQ) -> Chronic Respiratory Questionnaire (CRQ) (1.00)', 'Linear Analog Self-Assessment (LASA) -> Linear Analog Self-Assessment (LASA) (1.00)']",[],['Medical Research Council Dyspnea Score (MRC)']
Protocol_02,['Functional Assessment of Cancer Therapy - General (FACT-G)'],"['Cycle 1', 'Cycle 4', 'Treatment Discontinuation', 'Off Study']","National Cancer Institute 
",Oncology,['Functional Assessment of Cancer Therapy-General (FACT-G)'],"['Cycle 1', 'Cycle 4', 'Treatment Discontinuation', 'Off Study']",,1.0,1.0,1.0,1.0,['Functional Assessment of Cancer Therapy - General (FACT-G) -> Functional Assessment of Cancer Therapy-General (FACT-G) (1.00)'],[],[]
Protocol_03,"['Dermatology Life Quality Index (DLQI)', 'Itch Numeric Rating Scale (NRS)', 'Skin Discomfort/Pain Visual Analog Scale (VAS)', 'Patient Benefit Index (PBI)', 'European Quality of Life 5-Dimension Questionnaire (EQ-5D)', 'Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI: PSO)']","['Visit Number: 1   (Screening  )', 'Visit Number: Baseline 2   (Placebo-Controlled Phasea  )', 'Visit Number: 3', 'Visit Number: 4', 'Visit Number: 5', 'Visit Number: 6   (Apremilast Extension Phaseb  )', 'Visit Number: 7', 'Visit Number: 9/ETc', 'Visit Number: Baseline 2   (Placebo-Controlled Phasea  )', 'Visit Number: 3', 'Visit Number: 4', 'Visit Number: 5', 'Visit Number: 6   (Apremilast Extension Phaseb  )', 'Visit Number: 7', 'Visit Number: 9/ETc', 'Visit Number: Baseline 2   (Placebo-Controlled Phasea  )', 'Visit Number: 3', 'Visit Number: 4', 'Visit Number: 5', 'Visit Number: 6   (Apremilast Extension Phaseb  )', 'Visit Number: 7', 'Visit Number: 9/ETc', 'Visit Number: 4', 'Visit Number: 5', 'Visit Number: 7', 'Visit Number: 9/ETc', 'Visit Number: Baseline 2   (Placebo-Controlled Phasea  )', 'Visit Number: 5', 'Visit Number: 9/ETc', 'Visit Number: Baseline 2   (Placebo-Controlled Phasea  )', 'Visit Number: 5', 'Visit Number: 9/ETc']",Amgen Inc.,Immunology & Fibrosis Clinical Development,"['Dermatology Life Quality Index (DLQI)', 'Itch Numeric Rating Scale (NRS)', 'Skin Discomfort/Pain Visual Analog Scale (VAS)', 'Psoriasis Area and Severity Index (PASI)', 'European Quality of Life 5-Dimension Questionnaire (EQ-5D)', 'The Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI:', 'PSO)']","['Visit Number: 1 (Screening)', 'Visit Number: Baseline 2 (Placebo-Controlled Phasea )', 'Visit Number: 3', 'Visit Number: 4', 'Visit Number: 5', 'Visit Number: 6 (Apremilast Extension Phaseb )', 'Visit Number: 7 ', 'Visit Number: 9/ETc ', 'Visit Number: Baseline 2 (Placebo-Controlled Phasea )', 'Visit Number: 3', 'Visit Number: 4', 'Visit Number: 5', 'Visit Number: 6 (Apremilast Extension Phaseb )', 'Visit Number: 7', 'Visit Number: 9/ETc', 'Visit Number: Baseline 2 (Placebo-Controlled Phasea )', 'Visit Number: 3', 'Visit Number: 4', 'Visit Number: 5', 'Visit Number: 6 (Apremilast Extension Phaseb )', 'Visit Number: 7', 'Visit Number: 9/ETc', 'Visit Number: 1 (Screening)', 'Visit Number: Baseline 2 (Placebo-Controlled Phasea )', 'Visit Number: 3', 'Visit Number: 4', 'Visit Number: 5', 'Visit Number: 6 (Apremilast Extension Phaseb )', 'Visit Number: 7', 'Visit Number: 9/ETc', 'Visit Number: Baseline 2 (Placebo-Controlled Phasea )', 'Visit Number: 5', 'Visit Number: 9/ETc', 'Visit Number: Baseline 2 (Placebo-Controlled Phasea )', 'Visit Number: 5', 'Visit Number: 9/ETc']",,5.0,0.8333333333333334,0.7142857142857143,0.7692307692307692,"['Skin Discomfort/Pain Visual Analog Scale (VAS) -> Skin Discomfort/Pain Visual Analog Scale (VAS) (1.00)', 'Dermatology Life Quality Index (DLQI) -> Dermatology Life Quality Index (DLQI) (1.00)', 'European Quality of Life 5-Dimension Questionnaire (EQ-5D) -> European Quality of Life 5-Dimension Questionnaire (EQ-5D) (1.00)', 'Itch Numeric Rating Scale (NRS) -> Itch Numeric Rating Scale (NRS) (1.00)', 'Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI: PSO) -> The Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI: (0.98)']",['Patient Benefit Index (PBI)'],"['Psoriasis Area and Severity Index (PASI)', 'PSO)']"
Protocol_15,"['Numerical Analogue Mouth Pain Scale (Numerical Analog Pain Scale)', 'Numerical Analogue Self-Assessment (Numerical Analog Self-Assessment)', 'PRO-CTCAE (Mouth/throat sores, Sleep, Fatigue items) (PRO-CTCAE)', 'Patient Reported Mouthwash Use Frequency (Mouthwash Use Frequency)']","['', 'Baseline*', '', 'Baseline*', 'Weekly, for 8 weeks from start of treatment', '', 'Baseline*', 'Weekly, for 8 weeks from start of treatment', '', 'Weekly, for 8 weeks from start of treatment']",Alliance for Clinical Trials in Oncology,Oncology,"['Numerical Analogue Mouth Pain Scale', 'Numerical Analogue Self-Assessment', 'PRO-CTCAE items Mouth/throat sores, Sleep and Fatigue items (PRO-CTCAE)', 'Patient reported Mouthwash Use frequency']","['Baseline*', 'Weekly, for 8 weeks from start of treatment', 'Weekly, for 8 weeks from start of treatment', 'Baseline*', 'Weekly, for 8 weeks from start of treatment', 'Weekly, for 8 weeks from start of treatment']",,4.0,1.0,1.0,1.0,"['Numerical Analogue Mouth Pain Scale (Numerical Analog Pain Scale) -> Numerical Analogue Mouth Pain Scale (0.97)', 'Patient Reported Mouthwash Use Frequency (Mouthwash Use Frequency) -> Patient reported Mouthwash Use frequency (0.96)', 'PRO-CTCAE (Mouth/throat sores, Sleep, Fatigue items) (PRO-CTCAE) -> PRO-CTCAE items Mouth/throat sores, Sleep and Fatigue items (PRO-CTCAE) (0.96)', 'Numerical Analogue Self-Assessment (Numerical Analog Self-Assessment) -> Numerical Analogue Self-Assessment (0.94)']",[],[]
Protocol_42,"['Eczema-related Sleep Numeric Rating Scale (Eczema-related Sleep NRS)', 'Worst Daily Pruritus Numeric Rating Scale (Worst Daily Pruritus NRS)', 'Average Daily Pruritus Numeric Rating Scale (Average Daily Pruritus NRS)', 'Patient Global Impression of Bother (PGI-B)', 'Patient Global Impression of Severity (PGI-S)', 'Patient-Oriented Eczema Measure (POEM)', 'Dermatology Life Quality Index (DLQI)', 'EuroQoL 5-Dimension Health Questionnaire 5 Level (EQ-5D-5L)', '36-Item Short Form Health Survey (SF-36)', 'Work Productivity and Activity Impairment – General Health (WPAI-GH)', 'Hospital Anxiety and Depression Scale (HADS)', 'Treatment Satisfaction Questionnaire for Medicine (TSQM)']","['Visit: 3   (Initial treatment period  )', 'Visit: 16', 'Visit: 20', 'Visit: 24', 'Visit: 28', 'Visit: 3   (Initial treatment period  )', 'Visit: 16', 'Visit: 20', 'Visit: 24', 'Visit: 28', 'Visit: 3   (Initial treatment period  )', 'Visit: 16', 'Visit: 20', 'Visit: 24', 'Visit: 28', 'Visit: 3   (Initial treatment period  )', 'Visit: 16', 'Visit: 20', 'Visit: 24', 'Visit: 28', 'Visit: 3   (Initial treatment period  )', 'Visit: 16', 'Visit: 20', 'Visit: 24', 'Visit: 28', 'Visit: 3   (Initial treatment period  )', 'Visit: 18']",LEO Pharma A/S,Dermatology,"['Eczema-related Sleep numeric rating scale (Eczema-related Sleep NRS)', 'Worst Daily Pruritus numeric rating scale (Worst Daily Pruritus NRS)', 'Average Daily Pruritus numeric rating scale (Average Daily Pruritus NRS)', 'Patient Global Impression of Bother (PGI-B)', 'Patient Global Impression of Severity (PGI-S)', 'Patient-Oriented Eczema Measure (POEM)', 'Dermatology Life Quality Index (DLQI)', 'EuroQoL 5-Dimension Health Questionnaire 5 Level (EQ-5D-5L)', '36-Item Short Form Health Survey (SF-36)', 'Work Productivity and Activity Impairment 2013 General Health (WPAI-GH)', 'Hospital Anxiety and Depression Scale (HADS)', 'Treatment Satisfaction Questionnaire for Medicine (TSQM)']","['Visit: 3', 'Visit: 4', 'Visit: 5', 'Visit: 6', 'Visit: 7', 'Visit: 9', 'Visit: 12', 'Visit: 14', 'Visit: 18', 'Visit: 22', 'Visit: 26', 'Visit: 30', 'Visit: 3', 'Visit: 4', 'Visit: 5', 'Visit: 6', 'Visit: 7', 'Visit: 9', 'Visit: 12', 'Visit: 14', 'Visit: 18', 'Visit: 22', 'Visit: 26', 'Visit: 30', 'Visit: 3', 'Visit: 5', 'Visit: 7', 'Visit: 9', 'Visit: 12', 'Visit: 14', 'Visit: 18', 'Visit: 22', 'Visit: 26', 'Visit: 30', 'Visit: 3', 'Visit: 7', 'Visit: 12', 'Visit: 14', 'Visit: 18', 'Visit: 22', 'Visit: 26', 'Visit: 30', 'Visit: 3', 'Visit: 7', 'Visit: 12', 'Visit: 14', 'Visit: 18', 'Visit: 22', 'Visit: 26', 'Visit: 30', 'Visit: 3', 'Visit: 5', 'Visit: 7', 'Visit: 9', 'Visit: 12', 'Visit: 14', 'Visit: 18', 'Visit: 22', 'Visit: 26', 'Visit: 30', 'Visit: 4', 'Visit: 12', 'Visit: 16', 'Visit: 30']",,12.0,1.0,1.0,1.0,"['Eczema-related Sleep Numeric Rating Scale (Eczema-related Sleep NRS) -> Eczema-related Sleep numeric rating scale (Eczema-related Sleep NRS) (1.00)', 'Average Daily Pruritus Numeric Rating Scale (Average Daily Pruritus NRS) -> Average Daily Pruritus numeric rating scale (Average Daily Pruritus NRS) (1.00)', 'Worst Daily Pruritus Numeric Rating Scale (Worst Daily Pruritus NRS) -> Worst Daily Pruritus numeric rating scale (Worst Daily Pruritus NRS) (1.00)', 'Patient Global Impression of Bother (PGI-B) -> Patient Global Impression of Bother (PGI-B) (1.00)', 'Patient-Oriented Eczema Measure (POEM) -> Patient-Oriented Eczema Measure (POEM) (1.00)', 'Dermatology Life Quality Index (DLQI) -> Dermatology Life Quality Index (DLQI) (1.00)', 'EuroQoL 5-Dimension Health Questionnaire 5 Level (EQ-5D-5L) -> EuroQoL 5-Dimension Health Questionnaire 5 Level (EQ-5D-5L) (1.00)', 'Hospital Anxiety and Depression Scale (HADS) -> Hospital Anxiety and Depression Scale (HADS) (1.00)', 'Treatment Satisfaction Questionnaire for Medicine (TSQM) -> Treatment Satisfaction Questionnaire for Medicine (TSQM) (1.00)', 'Patient Global Impression of Severity (PGI-S) -> Patient Global Impression of Severity (PGI-S) (1.00)', '36-Item Short Form Health Survey (SF-36) -> 36-Item Short Form Health Survey (SF-36) (1.00)', 'Work Productivity and Activity Impairment – General Health (WPAI-GH) -> Work Productivity and Activity Impairment 2013 General Health (WPAI-GH) (0.96)']",[],[]
Protocol_39,"['Asthma Control Questionnaire–Interviewer Administered (ACQ-IA)', 'Pediatric Asthma Quality of Life Questionnaire with Standardized Activities–Interviewer Administered (PAQLQ(S)-IA)', 'Pediatric Rhinoconjunctivitis Quality of Life Questionnaire–Interviewer Administered (PRQLQ-IA)', 'EuroQol 5 dimension youth questionnaire (EQ-5D-Y)', ""Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ)""]","['Week: –4 (±1)   (SCRa  )', 'Week: 0   (b  RND  ) (Randomized Treatment Period  )', 'Week: 2', 'Week: 4', 'Week: 6', 'Week: 8', 'Week: 10', 'Week: 12', 'Week: 16', 'Week: 20', 'Week: 24', 'Week: 28', 'Week: 32', 'Week: 36', 'Week: 40', 'Week: 44', 'Week: 48   (Post-treatment Period  d  )', 'Week: 0   (b  RND  ) (Randomized Treatment Period  )', 'Week: 12', 'Week: 24', 'Week: 36', 'Week: 0   (b  RND  ) (Randomized Treatment Period  )', 'Week: 12', 'Week: 24', 'Week: 36']",Sanofi Group,Respiratory diseases,"['Asthma Control Questionnaire Interviewer Administered, 7-question version (ACQ-7-IA)', 'Asthma Control Questionnaire Interviewer Administered, 5-question version (ACQ-5-IA)', 'Pediatric Asthma Quality of Life Questionnaire with Standardized Activities Interviewer Administered (PAQLQ(S)-IA)', ""Paediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ)"", 'EuroQol 5-Dimension Youth (EQ-5D-Y)', 'Pediatric Rhinoconjunctivitis Quality of Life Questionnaire â\x80\x93 Interviewer', 'Administered (PRQLQ-IA)']","['Week -4 (Â±1) (SCRa )', 'Week 0 (b RND ) (Randomized Treatment Period )', 'Week 2', 'Week 4', 'Week 6', 'Week 8', 'Week 10', 'Week 12', 'Week 16', 'Week 20', 'Week 24', 'Week 28', 'Week 32', 'Week 36', 'Week 40', 'Week 44', 'Week 48 (Post-treatment Period d )', 'Week 52', 'Week 64', 'Week -4 (Â±1) (SCRa )', 'Week 0 (b RND ) (Randomized Treatment Period )', 'Week 2', 'Week 4', 'Week 6', 'Week 8', 'Week 10', 'Week 12', 'Week 16', 'Week 20', 'Week 24', 'Week 28', 'Week 32', 'Week 36', 'Week 40', 'Week 44', 'Week 48 (Post-treatment Period d )', 'Week 52', 'Week 64', 'Week 0 (b RND ) (Randomized Treatment Period )', 'Week 12', 'Week 24', 'Week 36', 'Week 52', 'Week 64']",Extracted tables data is missing.,5.0,1.0,0.7142857142857143,0.8333333333333333,"['Pediatric Asthma Quality of Life Questionnaire with Standardized Activities–Interviewer Administered (PAQLQ(S)-IA) -> Pediatric Asthma Quality of Life Questionnaire with Standardized Activities Interviewer Administered (PAQLQ(S)-IA) (1.00)', 'Pediatric Rhinoconjunctivitis Quality of Life Questionnaire–Interviewer Administered (PRQLQ-IA) -> Pediatric Rhinoconjunctivitis Quality of Life Questionnaire â\x80\x93 Interviewer (0.96)', ""Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ) -> Paediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ) (0.96)"", 'Asthma Control Questionnaire–Interviewer Administered (ACQ-IA) -> Asthma Control Questionnaire Interviewer Administered, 5-question version (ACQ-5-IA) (0.95)', 'EuroQol 5 dimension youth questionnaire (EQ-5D-Y) -> EuroQol 5-Dimension Youth (EQ-5D-Y) (0.83)']",[],"['Asthma Control Questionnaire Interviewer Administered, 7-question version (ACQ-7-IA)', 'Administered (PRQLQ-IA)']"
Protocol_19,['Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)'],[],Onconova Therapeutics Inc,Myelodysplastic Syndrome (MDS),['Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)'],"['Tests/Evaluations: Baseline/ C1D1b', 'Tests/Evaluations: Q4W for 12 Wk then Q8Wb']",,1.0,1.0,1.0,1.0,['Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) -> Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) (1.00)'],[],[]
Protocol_35,['EORTC QLQ-C30 (EORTC QLQ-C30)'],"['Study Procedure: Screening Visit X', 'Study Procedure: Day 1   (Cycles 1 through 16 (cycle length = 6 weeks)  )', 'Study Procedure: Follow-up Visits 1 and 21']","Regeneron Pharmaceuticals, Inc.",Cervical Cancer (Ontology),['European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)'],"['Study Procedure: Screening Visit X', 'Study Procedure: Day 1 (Cycles 1 through 16 (cycle length = 6 weeks) )', 'Study Procedure: Follow-up Visits 1 and 21']",,0.0,0.0,0.0,0.0,[],['EORTC QLQ-C30 (EORTC QLQ-C30)'],['European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)']
Protocol_23,['EQ5D5L Questionnaire (EQ5D5L)'],[],CharitÃ© UniversitÃ¤tsmedizin Berlin,Metastatic colorectal cancer,['EQ-5D-5L Quality of Life Questionnaire (EQ5D5L)'],[],Extracted tables data is missing.,1.0,1.0,1.0,1.0,['EQ5D5L Questionnaire (EQ5D5L) -> EQ-5D-5L Quality of Life Questionnaire (EQ5D5L) (0.82)'],[],[]
Protocol_28,"['Care Transitions Measure-15 (CTM-15) (CTM-15)', 'Preparedness for Caregiving Scale (PCS) (PCS)', 'McGill Quality of Life Questionnaire - Revised (MQoL-R) (MQoL-R)', 'Life Space Assessment (Life Space Assessment)', 'Hospice Enrollment (Hospice Enrollment)', 'Hospital Readmissions (Hospital Readmissions)']","['Assessments and Procedures: 7 Days Post-Discharge (+ 10/- 3 days)', 'Assessments and Procedures: 7 Days Post-Discharge (+/- 2 days)', 'Assessments and Procedures: 30 Days Post-Discharge (+/- 7 days)', 'Assessments and Procedures: 60 Days Post-Discharge (+/- 7 days)', 'Assessments and Procedures: 30 Days Post-Discharge (+/- 7 days)', 'Assessments and Procedures: 60 Days Post-Discharge (+/- 7 days)', 'Assessments and Procedures: 30 Days Post-Discharge (+/- 7 days)', 'Assessments and Procedures: 60 Days Post-Discharge (+/- 7 days)', 'Assessments and Procedures: 30 Days Post-Discharge (+/- 7 days)', 'Assessments and Procedures: 60 Days Post-Discharge (+/- 7 days)']",National Institute of Nursing Research (NINR),Transitional care,"['Care Transitions Measure-15 (CTM-15)', 'Preparedness for Caregiving Scale (PCS)', 'McGill Quality of Life Questionnaire-Revised (MQoL-R)', 'Life Space Assessment (LSA)', 'Zarit Caregiver Burden Scale (ZCBS)', 'Distress Thermometer (DT)', 'Number of Patient Falls with Injury and Without Injury (Falls Assessment)', 'MD Visit (MD Visit)', 'Hospice Enrollment (Hospice Enrollment)', 'Hospital Readmissions (Hospital Readmissions)', 'Emergency Department Use (ED Use)', 'Death Report by Caregiver (Death Report)']","['Assessments and Procedures: 7 Days Post- Discharge (+ 10/- 3 days)', 'Assessments and Procedures: 7 Days Post- Discharge (+/-2 days)', 'Assessments and Procedures: 30 Days Post- Discharge (+/- 7 days)', 'Assessments and Procedures: 60 Days Post- Discharge (+/-7 days)', 'Assessments and Procedures: 30 Days Post- Discharge (+/- 7 days)', 'Assessments and Procedures: 60 Days Post- Discharge (+/-7 days)', 'Assessments and Procedures: 30 Days Post- Discharge (+/- 7 days)', 'Assessments and Procedures: 60 Days Post- Discharge (+/-7 days)', 'Assessments and Procedures: 30 Days Post- Discharge (+/- 7 days)', 'Assessments and Procedures: 60 Days Post- Discharge (+/-7 days)', 'Assessments and Procedures: 30 Days Post- Discharge (+/- 7 days)', 'Assessments and Procedures: 60 Days Post- Discharge (+/-7 days)', 'Assessments and Procedures: 30 Days Post- Discharge (+/- 7 days)', 'Assessments and Procedures: 60 Days Post- Discharge (+/-7 days)', 'Assessments and Procedures: 30 Days Post- Discharge (+/- 7 days)', 'Assessments and Procedures: 60 Days Post- Discharge (+/-7 days)', 'Assessments and Procedures: 30 Days Post- Discharge (+/- 7 days)', 'Assessments and Procedures: 60 Days Post- Discharge (+/-7 days)', 'Assessments and Procedures: 30 Days Post- Discharge (+/- 7 days)', 'Assessments and Procedures: 60 Days Post- Discharge (+/-7 days)', 'Assessments and Procedures: 30 Days Post- Discharge (+/- 7 days)', 'Assessments and Procedures: 60 Days Post- Discharge (+/-7 days)']",,6.0,1.0,0.5,0.6666666666666666,"['Hospital Readmissions (Hospital Readmissions) -> Hospital Readmissions (Hospital Readmissions) (1.00)', 'Hospice Enrollment (Hospice Enrollment) -> Hospice Enrollment (Hospice Enrollment) (1.00)', 'Care Transitions Measure-15 (CTM-15) (CTM-15) -> Care Transitions Measure-15 (CTM-15) (0.99)', 'McGill Quality of Life Questionnaire - Revised (MQoL-R) (MQoL-R) -> McGill Quality of Life Questionnaire-Revised (MQoL-R) (0.99)', 'Preparedness for Caregiving Scale (PCS) (PCS) -> Preparedness for Caregiving Scale (PCS) (0.99)', 'Life Space Assessment (Life Space Assessment) -> Life Space Assessment (LSA) (0.88)']",[],"['Zarit Caregiver Burden Scale (ZCBS)', 'Distress Thermometer (DT)', 'Number of Patient Falls with Injury and Without Injury (Falls Assessment)', 'MD Visit (MD Visit)', 'Emergency Department Use (ED Use)', 'Death Report by Caregiver (Death Report)']"
Protocol_45,"['Patient Global Impression (PGI)', 'Work Productivity and Activity Impairment Questionnaire (WPAIQ)', 'NeuroQoL (NeuroQoL)']","['Period   (APPENDIX A: TIME  ): M1  Visit   (Part A  )', 'Period   (APPENDIX A: TIME  ): M2  Visit', 'Period   (APPENDIX A: TIME  ): M3  Visit', 'Period   (APPENDIX A: TIME  ): M4  Visit', 'Period   (APPENDIX A: TIME  ): M8  Visit   (Part B  )', 'Period   (APPENDIX A: TIME  ): Enrollment (Baseline)', 'Period   (APPENDIX A: TIME  ): M2  Visit', 'Period   (APPENDIX A: TIME  ): M4  Visit', 'Period   (APPENDIX A: TIME  ): Enrollment (Baseline)', 'Period   (APPENDIX A: TIME  ): M2  Visit', 'Period   (APPENDIX A: TIME  ): M4  Visit', 'Period   (APPENDIX A: TIME  ): M8  Visit   (Part B  )']","Regenesis Biomedical, Inc.",,"['Patient Global Impression (PGI)', 'Work Productivity and Activity Impairment Questionnaire (WPAIQ)', 'Neuro-QoL (NeuroQoL)']","['Period (APPENDIX A: TIME ): Enrollment (Baseline)', 'Period (APPENDIX A: TIME ): M2 Visit', 'Period (APPENDIX A: TIME ): M4 Visit', 'Period (APPENDIX A: TIME ): Enrollment (Baseline)', 'Period (APPENDIX A: TIME ): M2 Visit', 'Period (APPENDIX A: TIME ): M4 Visit', 'Period (APPENDIX A: TIME ): M8 Visit (Part B )']",,3.0,1.0,1.0,1.0,"['Work Productivity and Activity Impairment Questionnaire (WPAIQ) -> Work Productivity and Activity Impairment Questionnaire (WPAIQ) (1.00)', 'Patient Global Impression (PGI) -> Patient Global Impression (PGI) (1.00)', 'NeuroQoL (NeuroQoL) -> Neuro-QoL (NeuroQoL) (0.88)']",[],[]
Protocol_12,"['Functional Assessment of Cancer Therapy-Lung (FACT-L)', 'Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE)', 'Urinary Hesitancy Question (Urinary Hesitancy)', 'Bowel Function Diary (BF-Diary)', 'Pain and Pain Medication Diary (Pain Diary)']","['•', '•: Prior to the start of treatment*', '•: Every 6 weeks (+/- 7 days) until 1 year after start of treatment**', '•: Every 3 months (+/- 7 days) from 1 year to 2 years after the start of treatment', '•', '•: Prior to the start of treatment*', '•: Every 3 months (+/- 7 days) from 1 year to 2 years after the start of treatment', '•', '•: Prior to the start of treatment*', '•: Every 3 months (+/- 7 days) from 1 year to 2 years after the start of treatment', '3 and 6 weeks after start of treatment', 'Every 6 weeks* until 1 year after start of treatment', 'Every 3 months', '•', '•: Prior to the start of treatment*', '•: Every 3 months (+/- 7 days) from 1 year to 2 years after the start of treatment', '3 and 6 weeks after start of treatment', 'Every 6 weeks* until 1 year after start of treatment', 'Every 3 months', '•', '•: Prior to the start of treatment*', '•: Every 3 months (+/- 7 days) from 1 year to 2 years after the start of treatment', '•: Every 6 weeks (+/- 7 days) until 1 year after start of treatment**']",Alliance for Clinical Trials in Oncology,Oncology (Lung cancer),"['Functional Assessment of Cancer Therapy-Lung (FACT-L)', 'Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)', 'Urinary Hesitancy Question (Urinary Hesitancy)', 'Bowel Function Diary (BF-Diary)', 'Pain and Pain Medication Diary (Pain Diary)']","['Prior to the start of treatment*', 'Every 6 weeks (+/- 7 days) until 1 year after start of treatment**', 'Every 3 months (+/- 7 days) from 1 year to 2 years after the start of treatment', 'Prior to the start of treatment*', 'Every 6 weeks (+/- 7 days) until 1 year after start of treatment**', 'Every 3 months (+/- 7 days) from 1 year to 2 years after the start of treatment', 'Prior to the start of treatment*', 'Every 6 weeks (+/- 7 days) until 1 year after start of treatment**', 'Every 3 months (+/- 7 days) from 1 year to 2 years after the start of treatment', 'Prior to the start of treatment*', 'Every 6 weeks (+/- 7 days) until 1 year after start of treatment**', 'Every 3 months (+/- 7 days) from 1 year to 2 years after the start of treatment', 'Prior to the start of treatment*', 'Every 6 weeks (+/- 7 days) until 1 year after start of treatment**', 'Every 3 months (+/- 7 days) from 1 year to 2 years after the start of treatment']",,5.0,1.0,1.0,1.0,"['Functional Assessment of Cancer Therapy-Lung (FACT-L) -> Functional Assessment of Cancer Therapy-Lung (FACT-L) (1.00)', 'Urinary Hesitancy Question (Urinary Hesitancy) -> Urinary Hesitancy Question (Urinary Hesitancy) (1.00)', 'Bowel Function Diary (BF-Diary) -> Bowel Function Diary (BF-Diary) (1.00)', 'Pain and Pain Medication Diary (Pain Diary) -> Pain and Pain Medication Diary (Pain Diary) (1.00)', 'Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) -> Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) (0.99)']",[],[]
Protocol_04,"['Functional Assessment of Cancer Therapy - Prostate (FACT-P)', 'Functional Assessment of Cancer Therapy - Gynecologic Oncology Group - Neuropathy (FACT/GOG-NTX)', 'Patient-Reported Outcomes Measurement Information System Fatigue (PROMIS Fatigue)', 'Was It Worth It Questionnaire (WIWI)', 'End of Study Evaluation Form (End of Study Evaluation)']","['Fresh Tissue Collection   (Archival Tissue Submission (if available)  ) (Whole Body Bone Scan  ) (CT – Chest/Abdomen/Pelvis10  ) (PSA  ) (Testosterone  ) (Urinalysis  ) (Comprehensive Metabolic Panel (CMP)  ) (Complete Blood Count (CBC) with Platelet Count, Differential  ) (Physical Exam with ECOG  ) (Vital Signs  ) (Inclusion/Exclusion Criteria  ) (Informed Consent  ) (Protocol Procedures  )', 'Fresh Tissue Collection   (Archival Tissue Submission (if available)  ) (Whole Body Bone Scan  ) (CT – Chest/Abdomen/Pelvis10  ) (PSA  ) (Testosterone  ) (Urinalysis  ) (Comprehensive Metabolic Panel (CMP)  ) (Complete Blood Count (CBC) with Platelet Count, Differential  ) (Physical Exam with ECOG  ) (Vital Signs  ) (Inclusion/Exclusion Criteria  ) (Informed Consent  ) (Protocol Procedures  )', 'Fresh Tissue Collection   (Archival Tissue Submission (if available)  ) (Whole Body Bone Scan  ) (CT – Chest/Abdomen/Pelvis10  ) (PSA  ) (Testosterone  ) (Urinalysis  ) (Comprehensive Metabolic Panel (CMP)  ) (Complete Blood Count (CBC) with Platelet Count, Differential  ) (Physical Exam with ECOG  ) (Vital Signs  ) (Inclusion/Exclusion Criteria  ) (Informed Consent  ) (Protocol Procedures  )', 'Fresh Tissue Collection   (Archival Tissue Submission (if available)  ) (Whole Body Bone Scan  ) (CT – Chest/Abdomen/Pelvis10  ) (PSA  ) (Testosterone  ) (Urinalysis  ) (Comprehensive Metabolic Panel (CMP)  ) (Complete Blood Count (CBC) with Platelet Count, Differential  ) (Physical Exam with ECOG  ) (Vital Signs  ) (Inclusion/Exclusion Criteria  ) (Informed Consent  ) (Protocol Procedures  )']",Huntsman Cancer Institute (HCI),Oncology,"['Functional Assessment of Cancer Therapy - Prostate (FACT-P)', 'Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-NTX)', 'Patient-Reported Outcomes Measurement Information System Fatigue (PROMIS Fatigue)']","['Protocol Procedures: M0 (Day 1)', 'Protocol Procedures: M3', 'Protocol Procedures: M6 (Months (+/-4)', 'Protocol Procedures: M9 (days))', 'Protocol Procedures: M12', 'Protocol Procedures: M18', 'Protocol Procedures: M0 (Day 1)', 'Protocol Procedures: M3', 'Protocol Procedures: M6 (Months (+/-4)', 'Protocol Procedures: M9 (days))', 'Protocol Procedures: M12', 'Protocol Procedures: M18']",,3.0,0.6,1.0,0.7499999999999999,"['Functional Assessment of Cancer Therapy - Prostate (FACT-P) -> Functional Assessment of Cancer Therapy - Prostate (FACT-P) (1.00)', 'Patient-Reported Outcomes Measurement Information System Fatigue (PROMIS Fatigue) -> Patient-Reported Outcomes Measurement Information System Fatigue (PROMIS Fatigue) (1.00)', 'Functional Assessment of Cancer Therapy - Gynecologic Oncology Group - Neuropathy (FACT/GOG-NTX) -> Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-NTX) (0.78)']","['Was It Worth It Questionnaire (WIWI)', 'End of Study Evaluation Form (End of Study Evaluation)']",[]
Protocol_24,"['Skindex-16 (Skindex-16)', 'NCI PRO-CTCAE (NCI PRO-CTCAE)', 'Quality of Life Questionnaires (QoL)']","['Physical Examination, weight & Blood pressure   (Pregnancy Test  ) (Medical History2  ) (Informed Consent  ) (Inclusion/Exclusion Assessment  ) (-28 days  ): X   (±2 days  ) (Screening Pre-randomisation  )', 'Physical Examination, weight & Blood pressure   (Pregnancy Test  ) (Medical History2  ) (Informed Consent  ) (Inclusion/Exclusion Assessment  ) (-28 days  ): X   (Day 1  ) (Cycle 1  )', 'Physical Examination, weight & Blood pressure   (Pregnancy Test  ) (Medical History2  ) (Informed Consent  ) (Inclusion/Exclusion Assessment  ) (-28 days  ): X   (Day 15  )', 'Physical Examination, weight & Blood pressure   (Pregnancy Test  ) (Medical History2  ) (Informed Consent  ) (Inclusion/Exclusion Assessment  ) (-28 days  ): X   (Day 1  ) (Cycle 2  )', 'Physical Examination, weight & Blood pressure   (Pregnancy Test  ) (Medical History2  ) (Informed Consent  ) (Inclusion/Exclusion Assessment  ) (-28 days  ): X   (Day 15  )_1', 'Physical Examination, weight & Blood pressure   (Pregnancy Test  ) (Medical History2  ) (Informed Consent  ) (Inclusion/Exclusion Assessment  ) (-28 days  ): X   (+ 30 days  ) (Day 1  ) (Cycle 3 onwards1  )', 'Physical Examination, weight & Blood pressure   (Pregnancy Test  ) (Medical History2  ) (Informed Consent  ) (Inclusion/Exclusion Assessment  ) (-28 days  ): X   (±2 days  ) (Screening Pre-randomisation  )', 'Physical Examination, weight & Blood pressure   (Pregnancy Test  ) (Medical History2  ) (Informed Consent  ) (Inclusion/Exclusion Assessment  ) (-28 days  ): X   (Day 1  ) (Cycle 1  )', 'Physical Examination, weight & Blood pressure   (Pregnancy Test  ) (Medical History2  ) (Informed Consent  ) (Inclusion/Exclusion Assessment  ) (-28 days  ): X   (Day 15  )', 'Physical Examination, weight & Blood pressure   (Pregnancy Test  ) (Medical History2  ) (Informed Consent  ) (Inclusion/Exclusion Assessment  ) (-28 days  ): X   (Day 1  ) (Cycle 2  )', 'Physical Examination, weight & Blood pressure   (Pregnancy Test  ) (Medical History2  ) (Informed Consent  ) (Inclusion/Exclusion Assessment  ) (-28 days  ): X   (Day 15  )_1', 'Physical Examination, weight & Blood pressure   (Pregnancy Test  ) (Medical History2  ) (Informed Consent  ) (Inclusion/Exclusion Assessment  ) (-28 days  ): X   (+ 30 days  ) (Day 1  ) (Cycle 3 onwards1  )', 'Physical Examination, weight & Blood pressure   (Pregnancy Test  ) (Medical History2  ) (Informed Consent  ) (Inclusion/Exclusion Assessment  ) (-28 days  ): X   (±2 days  ) (Screening Pre-randomisation  )', 'Physical Examination, weight & Blood pressure   (Pregnancy Test  ) (Medical History2  ) (Informed Consent  ) (Inclusion/Exclusion Assessment  ) (-28 days  ): X   (Day 1  ) (Cycle 2  )']",Cambridge University Hospital NHS Foundation Trust,Oncology,"['Skindex-16 (Skindex-16)', 'Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)', 'European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)']","['Pre-randomisation (Screening)', 'Day 1 (Cycle 2)', 'Day 1 (Cycle 3 onwards 1)', 'Treatment (End of)', '(prior to progression)1 (4-weekly Follow-up) ', 'Progression (Disease)', 'after progression (3-Monthly Follow-up)', 'Pre-randomisation (Screening)', 'Day 1 (Cycle 2)', 'Day 1 (Cycle 3 onwards 1)', 'Treatment (End of)', '(prior to progression)1 (4-weekly Follow-up) ', 'Progression (Disease)', 'after progression (3-Monthly Follow-up)', 'Pre-randomisation (Screening)', 'Day 1 (Cycle 2)', 'Day 1 (Cycle 3 onwards 1)', 'Treatment (End of)', '(prior to progression)1 (4-weekly Follow-up) ', 'Progression (Disease)', 'after progression (3-Monthly Follow-up)']",Table with merged cells,1.0,0.3333333333333333,0.3333333333333333,0.3333333333333333,['Skindex-16 (Skindex-16) -> Skindex-16 (Skindex-16) (1.00)'],"['NCI PRO-CTCAE (NCI PRO-CTCAE)', 'Quality of Life Questionnaires (QoL)']","['Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)', 'European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)']"
Protocol_32,"['Worst Itching Intensity Numerical Rating Scale (NRS) (NRS)', 'Skindex-10 Scale (Skindex-10)', '5-D Itch Scale (5-D Itch)', 'Patient Global Impression of Change (PGIC)', 'Short Opiate Withdrawal Scale (ShOWS)']","['Study Procedures  Visit Days �: -7 to 1   (Day -7 to  Day 1  ) (Run-in  Period!  )', 'Study Procedures  Visit Days �: 85   (First Day of  Week13  ) (Double-blind End of  Treatment/  Early Termination  )', 'Study Procedures  Visit Days �: 85 to 98   (DP Days 2 -14  ) (Discontinuation  Period  )', 'Study Procedures  Visit Days �', 'Study Procedures  Visit Days �: 1   (M/Tu  ) (Weekl  ) (Double-blind Treatment Period  )', 'Study Procedures  Visit Days �: 8   (M/Tu  ) (Week 2 to 12  )', 'Study Procedures  Visit Days �: 85   (First Day of  Week13  ) (Double-blind End of  Treatment/  Early Termination  )', 'Study Procedures  Visit Days �', 'Study Procedures  Visit Days �: 1   (M/Tu  ) (Weekl  ) (Double-blind Treatment Period  )', 'Study Procedures  Visit Days �: 8   (M/Tu  ) (Week 2 to 12  )', 'Study Procedures  Visit Days �: 85   (First Day of  Week13  ) (Double-blind End of  Treatment/  Early Termination  )', 'Study Procedures: Week 4', 'Study Procedures: Week 8', 'Study Procedures: Week 12', 'Study Procedures: Week 24', 'Study Procedures: Week 36', 'Study Procedures: First Dialysis of Week  53  End of Treatment /arly  Termination', 'Study Procedures  Visit Days �: 85   (First Day of  Week13  ) (Double-blind End of  Treatment/  Early Termination  )', 'Study Procedures  Visit Days �: 85   (First Day of  Week13  ) (Double-blind End of  Treatment/  Early Termination  )', 'Study Procedures  Visit Days �: 85 to 98   (DP Days 2 -14  ) (Discontinuation  Period  )']","Cara Therapeutics, Inc.",Nephrology,"['Worst Itching Intensity Numerical Rating Scale (Worst Itching Intensity NRS)', 'Skindex-10 Scale (Skindex-10)', '5-D Itch Scale (5-D Itch)', 'Patient Global Impression of Change (PGIC)', 'Short Opiate Withdrawal Scale (ShOWS)']","['Visit Days (Study Procedures): -7 to 1 (Day -7 to Day 1) (Run-in Period)', 'Visit Days (Study Procedures): 1 (M/Tu)', 'Visit Days (Study Procedures): 3 (W/Th)', 'Visit Days (Study Procedures): 5 (F/Sa)', 'Visit Days (Study Procedures): 8 (M/Tu)', 'Visit Days (Study Procedures): 10 (W/Th)', 'Visit Days (Study Procedures): 12 (F/Sa)', 'Visit Days (Study Procedures): 85 (First Day of Week 13) (Double-blind End of Treatment Early Termination)', 'Visit Days (Study Procedures): 85 to 98 (DP Days 2b -14) (Discontinuation Period)', 'Visit Days (Study Procedures): 1 (M/Tu)', 'Visit Days (Study Procedures): 8 (M/Tu)', 'Visit Days (Study Procedures): 85 (First Day of Week 13) (Double-blind End of Treatment Early Termination)', 'Visit Days (Study Procedures): 1 (M/Tu)', 'Visit Days (Study Procedures): 8 (M/Tu)', 'Visit Days (Study Procedures): 85 (First Day of Week 13) (Double-blind End of Treatment Early Termination)', 'Study Procedures: Week 4', 'Study Procedures: Week 8', 'Study Procedures: Week 12', 'Study Procedures: Week 24', 'Study Procedures: Week 36', 'Study Procedures: First Dialysis of Week 53b End of Treatment /Early Termination (of Dosing)', 'Visit Days (Study Procedures): 85 (First Day of Week 13) (Double-blind End of Treatment Early Termination)', 'Visit Days (Study Procedures): 85 (First Day of Week 13) (Double-blind End of Treatment Early Termination)', 'Visit Days (Study Procedures): 85 to 98 (DP Days 2b -14) (Discontinuation Period)']","A lot of merged cells, organisation is difficult to understand",5.0,1.0,1.0,1.0,"['Patient Global Impression of Change (PGIC) -> Patient Global Impression of Change (PGIC) (1.00)', 'Short Opiate Withdrawal Scale (ShOWS) -> Short Opiate Withdrawal Scale (ShOWS) (1.00)', 'Skindex-10 Scale (Skindex-10) -> Skindex-10 Scale (Skindex-10) (1.00)', '5-D Itch Scale (5-D Itch) -> 5-D Itch Scale (5-D Itch) (1.00)', 'Worst Itching Intensity Numerical Rating Scale (NRS) (NRS) -> Worst Itching Intensity Numerical Rating Scale (Worst Itching Intensity NRS) (0.97)']",[],[]
Protocol_49,"['Fatigue Severity Scale (FSS)', 'Patient-Reported Outcomes Measurement Information System (PROMIS)']","['Visit 1', 'Exercise Training 5', 'Visit 2', 'Exercise Training 5']","National Institutes of Health (NIH),",Rheumatology,"['Patient Reported Outcomes Measurement Information System (PROMIS)', 'Fatigue Severity Scale (FSS)']","['Visit 2', 'Exercise Training 5', 'Visit 1', 'Exercise Training 5']",,2.0,1.0,1.0,1.0,"['Fatigue Severity Scale (FSS) -> Fatigue Severity Scale (FSS) (1.00)', 'Patient-Reported Outcomes Measurement Information System (PROMIS) -> Patient Reported Outcomes Measurement Information System (PROMIS) (0.99)']",[],[]
Protocol_08,"['Godin Leisure-Time Exercise Questionnaire (GLTEQ)', 'PROMIS-Cancer-Physical Function Measure (PROMIS-PF)', '36-Item Short Form Health Survey (SF-36)', 'Functional Assessment of Cancer Therapy - Fatigue (FACT-F)']",['Questionnaires   (Informed Consent  ) (Treating physician evaluation  ) (Eligibility review  ) (Procedures  )'],Oregon Health & Science University (OHSU),Oncology,"['Godin Leisure-Time Exercise Questionnaire (GLTEQ)', 'PROMIS-Cancer Physical Function Measure (PROMIS-Cancer-PF)', '36-Item Short Form Health Survey (SF-36)', 'Functional Assessment of Cancer Therapy-Fatigue (FACT-F)']","['Procedures: Baseline/W1', 'Procedures: Follow Up*', 'Informed Consent (Treating physician evaluation) (Eligibility review) (Procedures): Baseline /W1', 'Informed Consent (Treating physician evaluation) (Eligibility review) (Procedures): Follow Up*', 'Procedures: Baseline/W1', 'Procedures: Follow Up*', 'Informed Consent (Treating physician evaluation) (Eligibility review) (Procedures): Baseline /W1', 'Informed Consent (Treating physician evaluation) (Eligibility review) (Procedures): Follow Up*', 'Procedures: Baseline/W1', 'Procedures: Follow Up*', 'Informed Consent (Treating physician evaluation) (Eligibility review) (Procedures): Baseline /W1', 'Informed Consent (Treating physician evaluation) (Eligibility review) (Procedures): Follow Up*', 'Procedures: Baseline/W1', 'Procedures: Follow Up*', 'Informed Consent (Treating physician evaluation) (Eligibility review) (Procedures): Baseline /W1', 'Informed Consent (Treating physician evaluation) (Eligibility review) (Procedures): Follow Up*']",,4.0,1.0,1.0,1.0,"['Godin Leisure-Time Exercise Questionnaire (GLTEQ) -> Godin Leisure-Time Exercise Questionnaire (GLTEQ) (1.00)', '36-Item Short Form Health Survey (SF-36) -> 36-Item Short Form Health Survey (SF-36) (1.00)', 'Functional Assessment of Cancer Therapy - Fatigue (FACT-F) -> Functional Assessment of Cancer Therapy-Fatigue (FACT-F) (1.00)', 'PROMIS-Cancer-Physical Function Measure (PROMIS-PF) -> PROMIS-Cancer Physical Function Measure (PROMIS-Cancer-PF) (0.99)']",[],[]
Protocol_09,"['Functional Assessment of Cancer Therapy - Prostate (FACT-P) (FACT-P)', 'Short Form 36 Health Survey (SF-36) (SF-36)']","['Day 1 (±7 days)   (Treatment phase  )', 'Day 91 (±7 days)   (End of Study  )', 'Day 180 (±30 days)   (Lona-term follow-up""  )', 'Day 365 (±30 days)', 'Day 545 (±30 days)', 'Day 730 (±30 days)', 'Day 1 (±7 days)   (Treatment phase  )', 'Day 91 (±7 days)   (End of Study  )', 'Day 180 (±30 days)   (Lona-term follow-up""  )', 'Day 365 (±30 days)', 'Day 545 (±30 days)', 'Day 730 (±30 days)']",University of Washington / Seattle Cancer Care Alliance,Urologic oncology,"['Functional Assessment of Cancer Therapy - Prostate (FACT-P)', 'Short Form Health Survey (SF-36)']","['Day 1 (Â±7 days)', 'Day 91 (Â±7 days) (End of Study)', 'Day 180 (Â± 30 days) (Long-term follow-up)', 'Day 365 (Â±30 days)', 'Day 545 (Â±30 days)', 'Day 730 (Â±30 days)', 'Day 1 (Â±7 days)', 'Day 91 (Â±7 days) (End of Study)', 'Day 180 (Â± 30 days) (Long-term follow-up)', 'Day 365 (Â±30 days)', 'Day 545 (Â±30 days)', 'Day 730 (Â±30 days)']",,2.0,1.0,1.0,1.0,"['Functional Assessment of Cancer Therapy - Prostate (FACT-P) (FACT-P) -> Functional Assessment of Cancer Therapy - Prostate (FACT-P) (0.99)', 'Short Form 36 Health Survey (SF-36) (SF-36) -> Short Form Health Survey (SF-36) (0.90)']",[],[]
Protocol_48,"['International Knee Documentation Committee Subjective Knee Evaluation Form (IKDC-SKF)', 'Knee Injury and Osteoarthritis Outcome Score (KOOS)', 'Anterior Cruciate Ligament Quality of Life Questionnaire (ACL-QOL)', 'EuroQol Visual Analog Scale (EQ5D VAS)', 'EuroQol Index (EQ5D Index)', 'Marx Activity Rating Scale (Marx Activity)', 'Sports Participation Questionnaire (Sports Participation)', 'Return to Sport Questionnaire (Return to Sport)']","['Baseline', '6 weeks', '3 months', '6 months', '12 months', '24 months', 'Baseline', '6 weeks', '3 months', '6 months', '12 months', '24 months', 'Baseline', '6 weeks', '3 months', '6 months', '12 months', '24 months', 'Baseline', '6 weeks', '3 months', '6 months', '12 months', '24 months', 'Baseline', '6 weeks', '3 months', '6 months', '12 months', '24 months', '', 'Baseline', '6 weeks', '3 months', '6 months', '12 months', '24 months', 'Baseline', '6 months', '12 months', '24 months']","Canadian Institute of Health Research (CIHR)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)",Musculoskeletal Disorders,"['ACL Quality of Life Questionnaire (ACL-QOL)', 'International Knee Documentation Committee Subjective Knee Form (IKDC-SKF)', 'Knee injury and Osteoarthritis Outcome Survey (KOOS)', 'European Quality of Life Scale (EQ-5D)']","['Baseline', '6 weeks', '3 months', '6 months', '12 months', '24 months', 'Baseline', '6 weeks', '3 months', '6 months', '12 months', '24 months', 'Baseline', '6 weeks', '3 months', '6 months', '12 months', '24 months', 'Baseline', '6 weeks', '3 months', '6 months', '12 months', '24 months']",,3.0,0.375,0.75,0.5,"['International Knee Documentation Committee Subjective Knee Evaluation Form (IKDC-SKF) -> International Knee Documentation Committee Subjective Knee Form (IKDC-SKF) (0.96)', 'Knee Injury and Osteoarthritis Outcome Score (KOOS) -> Knee injury and Osteoarthritis Outcome Survey (KOOS) (0.91)', 'Anterior Cruciate Ligament Quality of Life Questionnaire (ACL-QOL) -> ACL Quality of Life Questionnaire (ACL-QOL) (0.81)']","['EuroQol Visual Analog Scale (EQ5D VAS)', 'EuroQol Index (EQ5D Index)', 'Marx Activity Rating Scale (Marx Activity)', 'Sports Participation Questionnaire (Sports Participation)', 'Return to Sport Questionnaire (Return to Sport)']",['European Quality of Life Scale (EQ-5D)']
Protocol_33,"['Symbol Digit Modality Test (SDMT)', 'Brief Visuospatial Memory Test - Revised (BVMT-R)', 'Pediatric Quality of Life Inventory (PedsQL)', 'Pediatric Neuro-QoL (Peds NeuroQoL)']","['Visit Daya: b  M36', 'Visit Daya: M18', 'Visit Daya: M24 (EOTP)', 'Visit Daya: b  M36', 'Visit Daya: M18', 'Visit Daya: M24 (EOTP)', 'Visit Daya: M30', 'Visit Daya: b  M36', 'Visit Daya: Relapse Visit', 'Visit Daya: M15', 'Visit Daya: M18', 'Visit Daya: M21', 'Visit Daya: M24 (EOTP)', 'Visit Daya: Relapse Visit  b', 'Visit Daya: b  M36']",Sanofi Genzyme,Neurology,"['Pediatric Quality of Life Inventory (PedsQL)', 'Pediatric Neuro Quality of Life (Ped NeuroQoL)']","['Visit number (Visit): V1 (Scrn. visitb)', 'Visit number (Visit): V3 (D-14 to D-7c) (DMT)', 'Visit number (Visit): V8 (M4)', 'Visit number (Visit): V12 (M8) (phase)', 'Visit number (Visit): V16v (M12)', 'Visit Day: M18', 'Visit Day: M24 (EOTP)', 'Visit Day: M36b', 'Visit Day: M48b', 'Visit Day: M60b', 'Visit number (Visit): V1 (Scrn. visitb)', 'Visit number (Visit): V3 (D-14 to D-7c) (DMT)', 'Visit number (Visit): V8 (M4)', 'Visit number (Visit): V12 (M8) (phase)', 'Visit number (Visit): V16v (M12)', 'Visit Day: M18', 'Visit Day: M24 (EOTP)', 'Visit Day: M36b', 'Visit Day: M48b', 'Visit Day: M60b']","In the last table, the header continues below the other rows instead of extending horizontally or being placed in a separate table",1.0,0.25,0.5,0.3333333333333333,['Pediatric Quality of Life Inventory (PedsQL) -> Pediatric Quality of Life Inventory (PedsQL) (1.00)'],"['Symbol Digit Modality Test (SDMT)', 'Brief Visuospatial Memory Test - Revised (BVMT-R)', 'Pediatric Neuro-QoL (Peds NeuroQoL)']",['Pediatric Neuro Quality of Life (Ped NeuroQoL)']
Protocol_25,"['European Organization for Research and Treatment of Cancer - Quality of Life Questionnaire (EORTC QLQ-C30)', 'European Organization for Research and Treatment of Cancer - Quality of Life Questionnaire - Neuroendocrine Carcinoid Module (EORTC QLQ-GI.NET21)', 'Quality of Life Questionnaire – Cancer Version (QLQ-C30)']","['Concept/measure: Baseline  Survey', 'Concept/measure: Follow- up  Surveys', 'Concept/measure: Baseline  Survey', 'Concept/measure: Follow- up  Surveys', 'Concept/measure: Baseline  Survey', 'Concept/measure: Follow- up  Surveys']",Patient-Centered Outcomes Research Institute,Oncology,"['European Organization for Research and Treatment of Cancer - Quality of Life Questionnaire (EORTC QLQ-C30)', 'European Organization for Research and Treatment of Cancer - Quality of Life Questionnaire - Neuroendocrine Carcinoid Module (EORTC QLQ-GI.NET21)']","['Concept/measure: Baseline Survey', 'Concept/measure: Follow- up Surveys', 'Concept/measure: Baseline Survey', 'Concept/measure: Follow- up Surveys']",,2.0,0.6666666666666666,1.0,0.8,"['European Organization for Research and Treatment of Cancer - Quality of Life Questionnaire (EORTC QLQ-C30) -> European Organization for Research and Treatment of Cancer - Quality of Life Questionnaire (EORTC QLQ-C30) (1.00)', 'European Organization for Research and Treatment of Cancer - Quality of Life Questionnaire - Neuroendocrine Carcinoid Module (EORTC QLQ-GI.NET21) -> European Organization for Research and Treatment of Cancer - Quality of Life Questionnaire - Neuroendocrine Carcinoid Module (EORTC QLQ-GI.NET21) (1.00)']",['Quality of Life Questionnaire – Cancer Version (QLQ-C30)'],[]
Protocol_05,"['Gum-Comfort Questionnaire (Gum Comfort)', 'Oral Health Impact Profile for Edentulous Patients (OHIP-Edent)', 'General Oral Health Assessment Index (GOHAI)']","['Procedure/Assessment: Visit 1 Screening / Baseline Day1', 'Procedure/Assessment: Visit 2 Day 7±1', 'Procedure/Assessment: Visit 3 Day 28±3', 'Procedure/Assessment: Visit 4 Day 56±3', 'Procedure/Assessment: Visit 5 Day 84±3', 'Procedure/Assessment: Visit 1 Screening / Baseline Day1', 'Procedure/Assessment: Visit 2 Day 7±1', 'Procedure/Assessment: Visit 3 Day 28±3', 'Procedure/Assessment: Visit 4 Day 56±3', 'Procedure/Assessment: Visit 5 Day 84±3', 'Procedure/Assessment: Visit 1 Screening / Baseline Day1', 'Procedure/Assessment: Visit 2 Day 7±1', 'Procedure/Assessment: Visit 3 Day 28±3', 'Procedure/Assessment: Visit 4 Day 56±3', 'Procedure/Assessment: Visit 5 Day 84±3']",GlaxoSmithKline Research & Development Limited,Dentistry,"['Gum Comfort Questionnaire (Gum Comfort)', 'Oral Health Impact Profile for Edentulous Adults (OHIP-Edent)', 'Geriatric Oral Health Assessment Index (GOHAI)']","['Procedure/Assessment: Visit 1 Screening / Baseline Day 1', 'Procedure/Assessment: Visit 2 Day 7 Â±  1 day', 'Procedure/Assessment: Visit 3 Day 28 Â± 3 days', 'Procedure/Assessment: Visit 4 Day 56 Â± 3 days', 'Procedure/Assessment: Visit 5 Day 84 Â± 3 days', 'Procedure/Assessment: Visit 1 Screening / Baseline Day 1', 'Procedure/Assessment: Visit 2 Day 7 Â±  1 day', 'Procedure/Assessment: Visit 3 Day 28 Â± 3 days', 'Procedure/Assessment: Visit 4 Day 56 Â± 3 days', 'Procedure/Assessment: Visit 5 Day 84 Â± 3 days', 'Procedure/Assessment: Visit 1 Screening / Baseline Day 1', 'Procedure/Assessment: Visit 2 Day 7 Â±  1 day', 'Procedure/Assessment: Visit 3 Day 28 Â± 3 days', 'Procedure/Assessment: Visit 4 Day 56 Â± 3 days', 'Procedure/Assessment: Visit 5 Day 84 Â± 3 days']",,3.0,1.0,1.0,1.0,"['Gum-Comfort Questionnaire (Gum Comfort) -> Gum Comfort Questionnaire (Gum Comfort) (1.00)', 'Oral Health Impact Profile for Edentulous Patients (OHIP-Edent) -> Oral Health Impact Profile for Edentulous Adults (OHIP-Edent) (0.96)', 'General Oral Health Assessment Index (GOHAI) -> Geriatric Oral Health Assessment Index (GOHAI) (0.86)']",[],[]
Protocol_13,"['Patient Symptom Diary (Symptom Diary)', 'FACES Pain Scale (FACES)', 'EQ-5D-5L (EuroQOL 5 dimensions) (EQ-5D-5L)', 'Vaccine Reaction Questionnaire (Vaccine Reaction)', 'Perceptions of the Vaccination Experience (Perceptions of Vaccination)', 'Late Life Function & Disability Instrument (LLFDI)']","['Procedure: Visit 1 Day 1', 'Procedure: Visit 3 Day 9 + 3', 'Procedure: Visit 1 Day 1', 'Procedure: Visit 3 Day 9 + 3', 'Procedure: Visit 1 Day 1', 'Procedure: Visit 3 Day 9 + 3', 'Procedure: Visit 1 Day 1', 'Procedure: Visit 1 Day 1', 'Procedure: Visit 3 Day 9 + 3', 'Procedure: Visit 4 Day 29 + 7', 'Procedure: Visit 1 Day 1', 'Procedure: Visit 3 Day 9 + 3']",Centers for Disease Control & Prevention (CDC),Infectious diseases and Preventive medicine,"['Late Life Function & Disability Instrument (LLFDI)', 'EuroQOL 5 dimensions-5 level (EQ-5D-5L)', 'EuroQOL visual analogue scale (EQ VAS)', 'Perceptions of Vaccination Experience questionnaire (PVEQ)', 'Faces Pain Scale (FPS)']","['Procedure: Visit 1 Day 1', 'Procedure: Visit 3 Day 9 + 3', 'Procedure: Visit 1 Day 1', 'Procedure: Visit 3 Day 9 + 3', 'Procedure: Visit 1 Day 1', 'Procedure: Visit 3 Day 9 + 3', 'Procedure: Visit 1 Day 1', 'Procedure: Visit 3 Day 9 + 3', 'Procedure: Visit 1 Day 1', 'Procedure: Visit 3 Day 9 + 3']",,4.0,0.6666666666666666,0.8,0.7272727272727272,"['Late Life Function & Disability Instrument (LLFDI) -> Late Life Function & Disability Instrument (LLFDI) (1.00)', 'EQ-5D-5L (EuroQOL 5 dimensions) (EQ-5D-5L) -> EuroQOL 5 dimensions-5 level (EQ-5D-5L) (0.89)', 'FACES Pain Scale (FACES) -> Faces Pain Scale (FPS) (0.84)', 'Perceptions of the Vaccination Experience (Perceptions of Vaccination) -> Perceptions of Vaccination Experience questionnaire (PVEQ) (0.82)']","['Patient Symptom Diary (Symptom Diary)', 'Vaccine Reaction Questionnaire (Vaccine Reaction)']",['EuroQOL visual analogue scale (EQ VAS)']
Protocol_44,"['Patient-Reported Performance Status (PRPS)', 'M.D. Anderson Symptom Inventory (MDASI)', 'EORTC Quality of Life Questionnaire (EORTC-QLQ-C30 & BR23)', 'Hospital Anxiety and Depression Scale (HADS)']","['Inclusion (baseline)', 'Midway (6 weeks)', 'Post-intervention (12 weeks)', 'Follow-up (16 weeks)', 'Inclusion (baseline)', 'Midway (6 weeks)', 'Post-intervention (12 weeks)', 'Follow-up (16 weeks)', 'Inclusion (baseline)', 'Midway (6 weeks)', 'Post-intervention (12 weeks)', 'Follow-up (16 weeks)', 'Inclusion (baseline)', 'Midway (6 weeks)', 'Post-intervention (12 weeks)', 'Follow-up (16 weeks)']",VELUX Foundation,Oncology,"['EORTC Quality of Life Questionnaire (EORTC QLQ-C30 & BR23)', 'Hospital Anxiety and Depression Scale (HADS)', 'M.D. Anderson Symptom Inventory (MDASI)']","['Inclusion (baseline)', 'Midway (6 weeks)', 'Post-intervention (12 weeks)', 'Follow-up (16 weeks)', 'Inclusion (baseline)', 'Midway (6 weeks)', 'Post-intervention (12 weeks)', 'Follow-up (16 weeks)', 'Inclusion (baseline)', 'Midway (6 weeks)', 'Post-intervention (12 weeks)', 'Follow-up (16 weeks)']",,3.0,0.75,1.0,0.8571428571428571,"['Hospital Anxiety and Depression Scale (HADS) -> Hospital Anxiety and Depression Scale (HADS) (1.00)', 'M.D. Anderson Symptom Inventory (MDASI) -> M.D. Anderson Symptom Inventory (MDASI) (1.00)', 'EORTC Quality of Life Questionnaire (EORTC-QLQ-C30 & BR23) -> EORTC Quality of Life Questionnaire (EORTC QLQ-C30 & BR23) (1.00)']",['Patient-Reported Performance Status (PRPS)'],[]
Protocol_29,"['European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)', 'FACT-Kidney Symptom Index - 15 (FKSI-15)', 'Perceived Stress Scale (PSS)']","['Assessment: W1D1  5', 'Assessment: W7D1', 'Assessment: W13D1', 'Assessment: W19D1', 'Assessment: W25D1   (Postdiscontinuation period  )', 'Assessment: W1D1  5', 'Assessment: W7D1', 'Assessment: W13D1', 'Assessment: W19D1', 'Assessment: W25D1   (Postdiscontinuation period  )', 'Assessment: W1D1  5', 'Assessment: W7D1', 'Assessment: W13D1', 'Assessment: W19D1', 'Assessment: W25D1   (Postdiscontinuation period  )']",Military Institute of Medicine,Oncology,"['European Organization for Research and Treatment of Cancer Quality of Life Questionnaire  (EORTC QLQ-C30)', 'FACT-Kidney Symptom Index - 15 (FKSI-15)', 'Perceived Stress Scale (PSS)']","['Assessment: W1D1 5', 'Assessment: W7D1', 'Assessment: W13D1', 'Assessment: W19D1', 'Assessment: W25D1', 'Assessment: After beginning of W25', 'Assessment: End-of- treatment visit', 'Assessment: W1D1 5', 'Assessment: W7D1', 'Assessment: W13D1', 'Assessment: W19D1', 'Assessment: W25D1', 'Assessment: After beginning of W25', 'Assessment: End-of- treatment visit', 'Assessment: W1D1 5', 'Assessment: W7D1', 'Assessment: W13D1', 'Assessment: W19D1', 'Assessment: W25D1', 'Assessment: After beginning of W25', 'Assessment: End-of- treatment visit']",,3.0,1.0,1.0,1.0,"['European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) -> European Organization for Research and Treatment of Cancer Quality of Life Questionnaire  (EORTC QLQ-C30) (1.00)', 'FACT-Kidney Symptom Index - 15 (FKSI-15) -> FACT-Kidney Symptom Index - 15 (FKSI-15) (1.00)', 'Perceived Stress Scale (PSS) -> Perceived Stress Scale (PSS) (1.00)']",[],[]
